

ANNUAL REPORT 2018

CHANGMAO BIOCHEMICAL ENGINEERING COMPANY LIMITED

常茂生物化學工程股份有限公司

(A Joint Stock Limited Company Incorporated In The People's Republic Of China)

(Stock Code: 954)



CONTENTS


•	Corporate Profile	2
•	Corporate Information	4
•	Chairman's Statement	5
•	Management Discussion and Analysis	12
•	Profile of Directors, Supervisors and Senior Management	15
•	Corporate Governance Report	21
•	Environmental and Social Report	34
•	Report of the Directors	42
•	Report of the Supervisory Committee	58
•	Independent Auditor's Report	
•	Consolidated Statement of Comprehensive Income	66
•	Consolidated Balance Sheet	67
•	Consolidated Statement of Changes in Equity	69
•	Consolidated Cash Flow Statement	70
•	Notes to the Consolidated Financial Statements	71
•	Five Year Summary	134
•	Glossary	135

CORPORATE PROFILE

Established in 1992, Changmao Biochemical Engineering Company Limited is a leading organic acid producer in the PRC. Changmao produces organic acids products for sales to food additive, chemical and pharmaceutical industries. Changmao's products conform to the highest international standards and are mainly exported to overseas such as Europe, Asia Pacific and America.

The core products of the Group are organic acids and their derivatives with four carbons in their structures including fumaric acid, maleic acid, L-malic acid, D-malic acid, DL-malic acid, L(+)-tartaric acid, D(-)-tartaric acid, DL-tartaric acid, L-aspartic acid and aspartame. These products are mainly used as food additives or medical inter-mediaries. The Group's major products are produced along vertical production chains. The major advantage of the production chains is that each of the products in the production chains is also a finished product for sales to customers.

PRODUCTION FLOWCHART OF CHANGMAO'S PRODUCTS




CORPORATE PROFILE

The Group persists in pursuing advanced technologies as its production direction and focuses in investment in new technology research and development which combines the production process with theoretical concepts. The Group received numerous awards in relation to production technologies including First Prize in Technological Achievement (技術發明一等獎) and Second Prize in Scientific Improvement (科技進步二等獎) in The Petroleum Chemical Industry in China (中國石油化工行業). The Group attained the ISO9001 Quality System Standards, Environmental Management System ISO14001 and FSSC22000 Food Safety System Certification. Its core product, L(+)-tartaric acid obtained the Food and Drug Administration (FDA) certificate. The Group's logo was also recognised as a Famous Trademark in the PRC (中國馳名商標).

The Group's major competitive edge is its delicate and advanced production system. Changmao successfully applied the theoretical concepts of enzyme technology and chirotechnology in its highly efficient and cost effective production process. The Group has two research and development centres, Chirotechnology Centre which is based in Changzhou, and the Shanghai Medical Life Science Research Centre Limited to research on new products and new production technologies. The Group will continue the production of food additives as its core business and develop new nutraceutical products to extend its production chain. The Group believes its strong capability in research and development would enable the Group to continue to grow.

GROUP STRUCTURE



CORPORATE INFORMATION

EXECUTIVE DIRECTORS

Mr. Rui Xin Sheng (Chairman)
Mr. Pan Chun (Chief Executive Officer)

NON-EXECUTIVE DIRECTORS

Mr. Zeng Xian Biao Mr. Yu Xiao Ping Ms. Leng Yi Xin Mr. Wang Jian Ping

INDEPENDENT NON-EXECUTIVE DIRECTORS

Prof. Ouyang Ping Kai Prof. Yang Sheng Li Ms. Wei Xin Ms. Au Fung Lan

SUPERVISORS NOMINATED BY SHAREHOLDERS

Ms. Zhou Rui Juan Mr. Lu A Xing

SUPERVISOR NOMINATED BY EMPLOYEES

Mr. Zhang Jun Peng

INDEPENDENT SUPERVISORS NOMINATED BY SHAREHOLDERS

Prof. Jiang Yao Zhong Mr. Geng Gang

COMPANY SECRETARY

Ms. Wan, Pui Ling Alice (CPA)

AUTHORISED REPRESENTATIVES

Mr. Rui Xin Sheng Ms. Wan, Pui Ling Alice (CPA)

COMPLIANCE OFFICER

Mr. Rui Xin Sheng

AUDIT COMMITTEE

Prof. Ouyang Ping Kai Prof. Yang Sheng Li Ms. Wei Xin* Ms. Au Fung Lan

REMUNERATION COMMITTEE

Mr. Rui Xin Sheng Prof. Ouyang Ping Kai Prof. Yang Sheng Li* Ms. Wei Xin Ms. Au Fung Lan

NOMINATION COMMITTEE

Mr. Rui Xin Sheng Prof. Ouyang Ping Kai* Prof. Yang Sheng Li Ms. Wei Xin Ms. Au Fung Lan

LEGAL ADDRESS

No. 1228 Chang Jiang Bei Road New North Zone Changzhou City Jiangsu Province, 213034 The PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

IN HONG KONG Room 54, 5/F, New Henry House 10 Ice House Street Central Hong Kong

PRINCIPAL BANKERS

Bank of China Changzhou Branch, the PRC Industrial and Commercial Bank of China Changzhou Branch, the PRC

HONG KONG SHARE REGISTRAR AND TRANSFER OFFICE

Computershare Hong Kong Investor Services Limited 46th Floor Hopewell Centre 183 Queen's Road East Hong Kong

AUDITORS

PricewaterhouseCoopers
Certified Public Accountants

COMPANY'S WEBSITE ADDRESS

www.cmbec.com.hk

STOCK CODE

954

^{*} chairman of the relevant committee

To the shareholders,

Results for the Year

The Group's sales revenue for the year ended 31 December 2018 was approximately Rmb639,120,000, which represented a slightly increase as compared to that in last year of Rmb630,841,000. Net profit attributable to the equity holders of the Company was approximately Rmb50,525,000, which was a significantly increase from Rmb3,382,000 in the last year.

In 2018, due to the domestic supply chain reform, the requirements for safety and environmental protection continued to become more rigorous, the Group was facing greater operational pressures compared with 2017. The Group was facing new challenges by the suspension of production of its wholly-owned subsidiary Changmao Biochemical Lianyungang Company Limited (hereinafter referred to as Lianyungang Changmao) for rectification as a result of the local government policies. Facing difficult domestic and foreign situations, all employees in the Group have worked together to respond positively, persisted in innovation and worked hard to overcome the difficulties. With the efforts of all employees, the Group's production, operation, research and development, management and other aspects have made great progress in 2018. Economic benefits have been significantly improved and overall developed to a positive and healthy direction.

Business Review

In 2018, the Group's production lines in Changzhou was the first in China to transform from using benzene-method to butane-method to manufacture maleic anhydride. The maleic anhydride production team studied constantly and broke through technical difficulties when facing difficulties. The manufacturing process was gradually restored to normal which lessen the pressure of downstream production costs and bought economic benefits to the Group. The recovery of by-product steam for further use in production also saved energy costs for the Group.

For a long time, the Group's aim is "To create value for customers and create benefit for the company" and made plans accordingly. The Group has been always committed to the highest standard. In order to meet the production needs and improve labour productivity, the Group actively applied automation and intelligent transformation on the production lines to improve product quality while reducing labour costs. At the same time, the Group has constantly upgraded its management system in production, organised labour competitions, improved the enthusiasm of employees in various departments, and carried out targeted process improvement and product quality improvement.

Carrying out cost reduction and efficiency improvement is the focus of production management for the Group in this year. The Group has paid attention to details, tapped potential transformation and upgraded basic facilities to achieve the purposes of saving energy, reducing emissions, and controlling production costs. In 2018, the low-pressure steam pipe and cold pipe projects of the Group's Changzhou plant effectively utilised different energy level allocations. The comprehensive utilisation rate of energy has been improved and the cost of purchased energy has been reduced which has achieved remarkable results.

In terms of sales, the Group adjusted its sales strategies timely and focused on sales channel control according to market changes. It has strengthened communication with end users and enhanced control power over the market. While improving sales management, the Group also strengthened procurement management. Through direct cooperation with suppliers, implementation of bidding and price comparison, strengthening the relationship with suppliers, reducing intermediate links, the Group has pursued a win-win situation.

Safety management is always the top priority of the Group's production management. In 2018, The Group focused on the improvement of the safety production management information system and the upgrading of the safety infrastructure. The Group passed the second-level safety production standardisation assessment of Jiangsu Province again in June 2018. The Group has always adhered to the strengthening of management processes with safety standardisation. Production safety was ensured through meticulous execution of the approval, monitoring and training of safety management personnel in respect of safety operation, constant self-correction in the production process and implantation of the safety enhancement.

In response to the new situation, the Group conscientiously followed the policies and laws and regulations in relation to environment protection imposed by the government. The Group continued to increase investment in environmental protection, took measures for energy saving, cost reduction and reduced emissions of wastes. In order to cope with the smoothing operation of the maleic anhydride production lines which used the butane-method, the Group has installed a new exhaust gas incinerator, the regenerative thermal oxidiser (RTO), to centralise incineration of production tail gas. A large amount of steam was recycled at the same time as the tail gas was incinerated which created objective economic benefits. In addition, the wastewater treatment plant has been updated and upgraded. A dedicated environmental protection department has ensured wastewater reached the discharge standard before emissions. The Group continued to improve its self-monitoring process to ensure the strict adherence to the 3 major types of pollutant discharge standards and actively fulfilled the corporate social responsibility.

In addition, the Group increased its investment in intelligent management in 2018, adopted computer process management control, re-regulated internal operations and improved the efficiency of interdepartmental cooperation. Internal management was effectively improved through the improvement of office automation. All employees can participate in risk identification and control that strengthening responsibility and execution.

Research and Development

1. Pharmaceutical Adjuvant Project

To extend its product chain and enhance added value of products, the Group actively carried out the development project of pharmaceutical adjuvant. The product breadth has extended from food additives to pharmaceutical adjuvant. The Group has actively promoted pharmaceutical adjuvants of aspartame, malic acid and other products and has slightly increase their sales this year.

Pharmaceutical adjuvant is the Group's focus in the medium to long run. The Group will continue to promote the research and development of pharmaceutical adjuvants, increase product categories, increase sales efforts, and achieve economic benefits.

2. Active Pharmaceutical Ingredient Project

Since the beginning of this year, the Group has promoted the L-malic acid active pharmaceutical ingredient research and development project, and was currently conducting quality research and stability investigation on the product. After the approval of L-malic acid active pharmaceutical ingredient and their preparations, the Group is expected to become the first L-malic acid active pharmaceutical ingredient supplier in China. The Group's research and development project of another active pharmaceutical ingredient, sodium pantothenate, has been submitted to the Jiangsu Provincial Drug Administration, and it is currently preparing for the production site inspection of the Provincial Drug Administration actively for GMP certification. The active pharmaceutical ingredient project will upgrade the existing products of the Group. It is an effective way to increase the added value of the products and will made contributions to the economic benefits of the Group.

The Group will put more efforts into research and development, strengthen cooperation with research institutes and pharmaceutical manufacturers, actively develop new products and expand production scope.

Key projects

1. Transforming the production lines to use butane to manufacture maleic anhydride in the Changzhou headquarter

In 2018, the Group completed the transformation of the maleic anhydride production lines which use the butane method to produce with annual production capacity 20,000 tonnes in the Changzhou headquarter. It has almost reached its full capacity recently. Transforming the production lines to use butane-method based on production lines that previously using benzene to manufacture maleic anhydride was the first in China and this has increased the difficulties of the project. The Group encountered different challenges, however, with the efforts of all employees of the Group by paying attention to details, tapping potential transformation and process optimisation, the project was completed successfully and maintained stable production.

The transformation of production lines, using butane instead of benzene as a raw material to manufacture maleic anhydride have reduced the emission of carbon dioxide which is clean and environmentally friendly and is in line with the government's requirements for safety and environmental protection. It is in line with the trend of international food additives manufacturing and also a starting point for the long-term economic benefits to control costs from the source and enhance the market competitiveness in long run.

2. Development of Changmao Biochemical Lianyungang Limited

Since the end of 2017, some enterprises in the Lianyungang have experienced safety and environmental accidents which were exposed by the media and caused a relatively bad social impact. In early 2018, Jiangsu Province stopped production of all enterprises in Lianyungang industrial district for rectification. Lianyungang Changmao has strictly complied various policies and laws and regulations imposed by the government since established, carried out projects and plant construction in accordance with national regulations of safety and environmental protection. As Lianyungang Changmao was located in the affected area, its production was suspended since early 2018 has had a major negative impact on the Group's economic efficiency.

During the suspension period, Lianyungang Changmao has actively implemented the procedures in later stage of the construction project, started the construction and paved the roads of the plant. In addition, Lianyungang Changmao self-examined its safety and environmental protection in the plant area and well prepared for the resumption of production at any time. The management has assessed the safety facilities of Lianyungang Changmao according to the government's requirements and believes that the relevant standards have been complied with. The management has filed an application for resumption of production, and is waiting for the approval of the relevant departments for fully resumption of production.



Environmental protection facilities



Incinerator



Maleic anhydride production line



Malic acid production line

Outlook and Prospect

The Group adheres to the economic efficiency, and is customer-oriented and relies on the advantages of the existing product chain to maintain its leading position in the industry. As a manufacturing enterprise, the Group will insist to reduce costs and increase efficiency, enhance scale effects, and continuously to improve product quality, and firmly establish Changmao brand and image in the future. The Group will focus on the following areas specifically:

Group.

1. Accelerating technology innovation and promoting product upgrade

The Group will continue to increase investment in technology innovation to consolidate its existing resources and research team. Relying on technological advancement and accelerating the development of new products such as L-malic acid active pharmaceutical ingredients, new feed additive PQQ and pharmaceutical adjuvant, it will build a more optimised product mix through cultivating new products which are safe, environmentally friendly and with strong competitiveness, highlighting its focus and increasing speed. Moreover, it will optimise its product structure, promote the upgrading and extension of existing product chains, and enhance the

Group's competitiveness in the high-end product market, and to seek new profit source of the

- 2. Promoting the development of Lianyungang project and taking advantages of productivity Lianyungang Changmao is a major development project of the Group in coming years. The construction of the new production plant in Lianyungang aimed to enhance the Group's product chain and large-scale production advantages, and provide raw materials for the world's high-end food and pharmaceutical manufacturers. After Lianyungang Changmao plant put into production, it will have more production cost advantages over the plant in Changzhou in the future, which will be the new force and become the Group's new profit center.
- 3. Enhancing safety and environmental protection and resisting policy risks
 With the laws and regulations related to safety and environmental protection becoming stricter, the elimination of small and medium-sized enterprises that failed to meet the standards were accelerated, leaving the industry to further concentrated on strong enterprises that complied with the relevant requirements. The Group has strictly complied with various safety and environmental regulations and this has transformed into a competitive advantage. In the future, the Group will continue to strengthen safety control, pay attention to safety risks, improve the safety of the production environment, and reduce and eliminate safety accidents. The Group will continue to promote clean production and implement pollution prevention, endeavor to become an environment-friendly enterprise which saves energy and reduces emissions of wastes to reduce the impact of policy risks on production and operation, and paves the way for the Group's sustainable development.
- 4. Focusing on market expansion and develop markets of high-end customers

 The Group's sales team strived to develop markets of major customers and end-customers, be customer-oriented, meet customer needs through the improvement of product quality and service, enhance the reputation and add value to the Changmao brand, thereby to enhance the overall competitive advantages. Facing the ever-changing domestic and international markets, the Group will actively adjust its sales strategy to improve the response to the market and its power over the markets. The markets of domestic sales and foreign sales will complement each other. In addition, the Group strived to establish close cooperation with customers and pursue a win-win situation to reduce risks together.

There will be opportunities and challenges in the future. The Group will continue the production of food additives as its core business and will increase the competitiveness of its existing products by exploring new markets and new application areas. The Group will capitalise its research and production strengths to develop new functional food additives, pharmaceutical intermediaries and nutraceutical products, etc. to continue to extend its production chain, to become bigger and stronger with great results.

The Group's long-term and stable development relies on the strong support from all shareholders. I would like to express my most sincere gratitude to the investors on behalf of the Board.

Rui Xin Sheng Chairman

The PRC, 12 March 2019

MANAGEMENT DISCUSSION AND ANALYSIS

ANALYSIS OF KEY PERFORMANCE INDICATORS

Revenue (2018: Rmb639,120,000; 2017: Rmb630,841,000) and gross profit margin (2018: 20.3%; 2017: 11.9%)

The increase in revenue was mainly due to the increase in product prices compared to 2017. The Group began to transform the maleic anhydride production line that uses new materials in Changzhou in 2017. After the completion of the transformation in 2018, the change of raw materials and the recycling of energy have saved production costs. At the same time, the Group is committed to energy conservation and emission reduction to increase labour productivity to control production costs which led to the increase in efficiency, and increased the gross profit margin.

Selling and administrative expenses (2018: Rmb78,723,000; 2017: Rmb80,853,000)

The Group's measures to reduce staffing and increase efficiency in 2018 achieved certain results, and the level of sales and administrative expenses was slightly lower than that in 2017. In addition, according to the incentive bonus plan of the Group, the incentive bonus for the year ended 31 December 2018 was Rmb1,809,000 (2017: Nil).

Other income (2018: Rmb4,018,000; 2017: Rmb12,784,000)

The decrease in other income in 2018 compared to that in 2017 was mainly due to the recognition of government subsidies for the year ended 31 December 2017, which included a one-off government subsidy in relation to an organic acid research project totalling Rmb7,221,000.

Other gains/(losses), net (2018: gains of Rmb1,737,000; 2017: losses of Rmb5,889,000)

The net gains were mainly attributable to the exchange gains of approximately Rmb1,816,000 in 2018, compared to other net losses in 2017 which mainly caused by the exchange losses of approximately Rmb3,033,000.

Finance (costs)/income, net (2018: costs of Rmb853,000; 2017: income of Rmb29,000)

The Group did not capitalise interest in 2018 (the interest expense capitalised in 2017 was Rmb1,059,000). The interest expense before deducting the interest capitalised was Rmb1,149,000 (2017: Rmb1,291,000), and the decrease in interest expense was due to the decrease in average bank loans compared to that in last year.

Income tax (expense)/credit (2018: expense of Rmb4,692,000; 2017: credit of Rmb1,456,000)

The Company, being qualified as a New and High Technology Enterprise, is entitled to a preferential CIT rate of 15% for the year ended 31 December 2018. Other subsidiaries of the Group in Mainland China are subject to a standard tax rate of 25%. Tax credit resulted for the year ended 31 December 2018 mainly because of the recognition of deferred tax assets on tax loss of a subsidiary. For details of the difference on the tax on the Group's profit before income tax and the theoretical amount that would arise using the weighted average tax rate applicable to the results of the consolidated entities, please refer to note 9 to the consolidated financial statements.

MANAGEMENT DISCUSSION AND ANALYSIS

Profit for the year attributable to the equity holders of the Company

For the year ended 31 December 2018, the Group recorded a profit attributable to equity holders of the Company of approximately Rmb50,525,000 (2017: Rmb3,382,000), which was significantly higher than that in last year. The increase in net profit was mainly due to the increase in gross profit margin, the contribution of Changzhou headquarters maleic anhydride production line to the cost control, and the continuous improvement of operating efficiency.

SEGMENTAL INFORMATION

Some of the Group's products are exported to Europe, Asia Pacific and America. As expressed as a percentage of revenue, export sales (excluding sales through import-export agents in the PRC) accounted for approximately 49% (2017: 54%) of the Group's revenue while domestic sales in the PRC accounted for approximately 51% (2017: 46%) of the Group's revenue.

EXPOSURE TO FLUCTUATIONS IN EXCHANGE RATES AND RELATED HEDGES

The Group mainly operates in the PRC. Substantially all of its assets, liabilities and capital expenditure are located or incurred in Mainland China. Sales are made to customers in the PRC as well as overseas customers while purchases are mainly from suppliers in the PRC. The Group is therefore exposed to foreign exchange risk arising from currency exposures, primarily with respect to USD. Management periodically monitors foreign currency exposures and considers hedging significant foreign currency exposure should the need arises. The Group did not use any forward foreign exchange contracts to hedge the USD exposures during the year. As at 31 December 2018, the Group had no outstanding forward foreign exchange contracts.

LIOUIDITY AND FINANCIAL RESOURCES

As at 31 December 2018, the Group had total outstanding bank borrowings of Rmb39,311,000 (2017: Rmb54,007,000). The outstanding bank borrowings as at 31 December 2018 were unsecured and were all repayable within one year. The Company expects to renew the bank borrowings in due time if necessary. The average effective interest rate of all the outstanding bank loans as at 31 December 2018 was approximately 3.8% (2017: 2.7%) per annum.

Except for the bank borrowings disclosed above, as at 31 December 2018 and 2017, the Group did not have any committed borrowing facilities.

The Group generally finances its operations with equity fundings and bank borrowings. Excess cash held by the Group is generally placed at banks to earn interest income.

As at 31 December 2018, the Group had capital commitments for property, plant and equipment amounting to approximately Rmb12,328,000 (2017: Rmb7,261,000). These capital commitments are mainly used for the modification of production lines. The Group intends to finance the capital commitment by cash flows generated from the Group's operations and/or bank financings.

MANAGEMENT DISCUSSION AND ANALYSIS

The Group did not have any charge on its assets during the year ended 31 December 2018. The liabilities-to-assets ratio (calculated based on total liabilities divided by total assets) was 13.8% (2017: 20.7%) as at 31 December 2018. As at 31 December 2018, the Group's cash and cash equivalents amounted to Rmb81,398,000 (2017: Rmb68,752,000). The Directors believe that the Group is in a healthy financial position.

EMPLOYEES

Including the Directors and Supervisors, as at 31 December 2018, the Group employed a total of 479 employees (2017: 577 employees). Employees are remunerated in accordance with the nature of the job and also on individual merit. Total amount of staff costs for the year ended 31 December 2018 was approximately Rmb69,859,000 (2017: Rmb69,044,000). The incentive bonus for the directors and staff of the Group was Rmb1,809,000 (2017: Nil) for the year ended 31 December 2018. Excluding the incentive bonus, the cost of staff wages, benefits and retirement was approximately Rmb68,050,000 (2017: Rmb69,044,000), which was lower than that in 2017 because the average number of employees was lower than that of last year.

Under the staff incentive scheme for each of the three years ended 31 December 2019, so long as the audited profits (or, where applicable, combined or consolidated profits) attributable to the shareholders (after taxation and non-controlling interest (if any) but before payment of the bonuses referred to below) amount to not less than Rmb40 million (the "Target Profit"):

- (a) a sum equivalents to 5% of the amount in excess of the Target Profit will be payable to Mr. Rui Xin Sheng as a bonus for the relevant year;
- (b) a sum equivalents to 5% of the amount in excess of the Target Profit will be payable to the general manager and all the Directors (other than Mr. Rui Xin Sheng and the independent non-executive Directors) for the time being of the Company as a bonus for the relevant year; and
- (c) a sum equivalents to 5% of the amount in excess of the Target Profit will be payable as bonus to all the employees (including supervisors, but excluding the Directors and the independent supervisors) of the Company and its subsidiaries (if any) from time to time, the basis of apportionment of which will be determined by the Board at its discretion.

SIGNIFICANT INVESTMENTS

There are no significant investments held by the Group as at 31 December 2018 and 2017.

CHANGES IN THE COMPOSITION OF THE GROUP DURING THE YEAR

There are no material acquisitions and disposals of subsidiaries and affiliated companies by the Group during the year ended 31 December 2018.

CONTINGENT LIABILITIES

As at 31 December 2018 and 31 December 2017, the Group did not have any material contingent liabilities.

DIRECTORS

Executive Directors

Mr. Rui Xin Sheng (芮新生), aged 62, is the chairman of the Board, an executive Director and the compliance officer of the Company. He is a researcher and a senior engineer of the Company. He was one of the founders of the Company in December 1992. He is also the director of Shanghai Life Sci, director and authorised representative of Shanghai Changmao and the director of Changmao (Hong Kong) Company Limited. Mr. Rui graduated from Jiangsu Institute of Technology (江蘇化工學院) with a bachelor degree in organic synthesis in 1982. He obtained an executive master of business administration in the Nanjing University (南京大學) in 2005. He is the vice chairman of the Committee of Biochemical Engineering of the Chemical Industry and Engineering Society of China (中國化工學會生物化工專業委員會), the deputy managing director of the Association of Biochemistry of China (中國生物化工協會), the deputy managing director of Jiangsu Commission of Biotechnology (江蘇省生物技術協會) and a part-time professor at the Nanjing University of Technology (南京工業大學). Owing to his significant achievement in the field of biochemistry, Mr. Rui received numerous awards including the First Class Award of Scientific Development and Technology Improvement in Changzhou (常州市技術改造一等獎) and the Second Prize of Changzhou City Scientific and Technological Achievement (常州市科技進步二等獎) in 1997. The Concurrent Production Technology invented by Mr. Rui, Ms. Leng Yi Xin and Mr. Jiang Jun Jie obtained patent in the PRC in 1998. Other awards obtained by Mr. Rui include the Fourth Annual Excellent Scientists of Changzhou City (常州市第四屆傑出科技人員) in 1999, DuPont Innovation Award and Youth Expert with Excellent Contribution in Jiangsu Province (江蘇省有突 出貢獻的中青年專家) in 2000, the First Class Award of State Technological Achievement (國家科 技進步一等獎) in 2001, Innovative Entrepreneur of Jiangsu Province (江蘇省創新創業人才獎), the Second Class Award of Petrol Chemical Industry Technological Achievement in the PRC (中國石油 化學工業行業科技進步二等獎) in 2003 and the First Class Award of Jiangsu Province Technological Achievement (江蘇省科學技術進步一等獎) in 2005. He is currently a director of Shuguang Factory. Mr. Rui is the spouse of Ms. Leng Yi Xin (a non-executive Director).

Mr. Pan Chun (潘春), aged 49, is an executive Director and the general manager (chief executive officer) of the Company. He is also the director and authorised representative of Lianyungang Changmao. He obtained a bachelor degree in industrial analysis from the department of applied chemistry of the Nanjing University of Technology (南京工業大學) in 1993. Mr. Pan is recognised as a senior engineer by the Jiangsu Provincial Personnel Department (江蘇省人事廳). Mr. Pan is responsible for the management of production, safety, environment protection, equipment management, purchasing and domestic sales of the Company. Mr. Pan received the First Class Award of Changzhou Technological Achievement (常州市技術改造一等獎) in 1997. Mr. Pan received the First Class Award of Technological Invention (技術發明一等獎) from China Petroleum and Chemical Industry Association (中國石油和化學工業協會) in 2003, May 1st Labour Medal of Changzhou City (常州市五一勞動獎章) in 2011 and Model Worker of China Light Industry (中國輕工行業勞動模範) in 2012. Mr. Pan joined the Company in August 1993.

DIRECTORS (Continued)

Non-executive Directors

Mr. Zeng Xian Biao (曾憲彪), aged 76, is a non-executive Director. Mr. Zeng graduated from Nanjing Petrochemistry School (南京石油工業學校) in 1961. He has extensive experience engaging in research, development and production management in the field of chemistry. Mr. Zeng received various awards including the Golden Prize of Technological Improvement-Maleic Anhydride 2000t/a (順酐2000t/a技改省金牛獎) from the State Economic Commission (國家經濟委員會), Maleic Anhydride 3000t/a Technology Improvement (3000t/a順酐重點技改先進個人), Municipal Contribution Award for the Ninth Five-year Period and the Millennium (市九五跨世紀奉獻獎) and the Second Annual State Award for Technological Development (省第二次合理化建議科技成果獎). Mr. Zeng is currently a director of Shuguang Factory. Mr. Zeng joined the Company in December 1992.

Mr. Yu Xiao Ping (虞小平), aged 63, is a non-executive Director. Mr. Yu graduated from East China Normal University (華東師範大學) with a bachelor degree in English in 1977. He holds directorships in various pharmaceutical and investment companies in the PRC. Besides his experience in trading of pharmaceutical products, he has experience in promoting and facilitating the inspection and approval from the U.S. Food and Drug Administration for various PRC pharmaceutical products, of which he became the executive agent for these pharmaceutical products and has established a trading business in the United States of America. Mr. Yu joined the Company in December 1992.

Ms. Leng Yi Xin (冷一欣), aged 57, is a non-executive Director. She is also the director of Shanghai Life Sci and general manager of Shanghai Changmao. She graduated from the Jiangsu Institute of Technology (江蘇化工學院) with a bachelor degree in organic synthesis in 1982 and subsequently obtained a master degree in chemical engineering from Nanjing University of Technology (南京 工業大學) in 1996 and obtained a doctorate in bio-chemical engineering from Nanjing University of Technology in 2005. She is also a professor of the department of chemical engineering of the School of Petrochemical Engineering in Changzhou University (常州大學石油化工學院). Ms. Leng has participated in various research projects and published more than 50 theses. As mentioned above, Ms. Leng is one of the inventors of the Concurrent Production Technology. She obtained the Second Class Award of Technological Invention (技術發明二等獎) from China Petroleum and Chemical Industry Association (中國石油和化學工業協會) in 2004. She also obtained the First Class Award of Jiangsu Province Technological Achievement (江蘇省科學技術進步一等獎) in 2005 and the Third Class Award of Jiangsu Province Technological Achievement (江蘇省科學技術進步三等獎) in 2010. She is the spouse of Mr. Rui (the chairman of the Board and an executive Director). She joined the Company in June 2001.

Mr. Wang Jian Ping (王建平), aged 57, is a non-executive Director. He graduated from Shanghai Jiao Tong University (上海交通大學) with a bachelor of engineering degree in 1983 and subsequently obtained a master of engineering degree from Shanghai Jiao Tong University (上海交通大學) in 1986. Mr. Wang is currently a general manager of Shanghai Technology Entrepreneur Investment Company Limited (上海科技創業投資股份有限公司). Mr. Wang has been a director of the 704 Research Centre of the Seventh Institute of the China Shipping Company (中國船舶總公司七院704研究所) and a visiting scholar of the department of energy in the University of Leeds. Mr. Wang was first appointed as a non-executive Director in June 2007.

DIRECTORS (Continued)

Independent non-executive Directors

Prof. Ouyang Ping Kai (歐陽平凱), aged 73, is an independent non-executive Director. He graduated from Tsinghua University (清華大學) with a bachelor degree in 1968 and subsequently obtained a master degree in chemistry research from the same university in 1981. From 1985 to 1987, he was a visiting scholar of the University of Waterloo, Ontario, Canada. Prof. Ouyang is an academician of the Chinese Academy of Engineering (中國工程院). He was the President of Nanjing University of Technology (南京工業大學) and instructed dozens of master and doctorate students. He also holds memberships and positions in various science and academic institutions. Prof. Ouyang obtained various awards including the First Prize of the State Technological Achievement (國家科技進一等獎) in 2001, the Technology Achievement Award from the Ho Leung Ho Lee Foundation, Dupont Innovation Award and several other awards of national level. Prof. Ouyang published more than 180 theses and two publications. Prof. Ouyang was first appointed as an independent non-executive Director in June 2001.

Prof. Yang Sheng Li (楊勝利), aged 78, is an independent non-executive Director. Prof. Yang is a researcher of Shanghai Research Center of Biotechnology Chinese Academy of Science (中國科學院上海生物工程研究中心). In 1997, he became the academician of the Chinese Academy of Engineering (中國工程院). Prof. Yang has long been engaging in research relating to genetic function and structure and genetic engineering. He instructed dozens of master students and doctorate students and published more than 80 theses. Prof. Yang received the First Class Award of Technological Achievement (科技進步一等獎) from the Chinese Academy of Science (中國科學院) in 1988, the Second Prize of Yilide Technology (第二屆億利達科技獎) from the Chinese Academy of Science (中國科學院) in 1989, and the First Prize of Innovative Worker (先進工作者一等獎) from the Committee of the Ministry of Science and Technology of the PRC (中國科技部委員會). Prof. Yang was first appointed as an independent non-executive Director in June 2001.

Ms. Wei Xin (衛新), aged 51, is an independent non-executive Director. Ms. Wei is a certified public accountant in the PRC. She graduated from Soochow University (蘇州大學) in accountancy in 1989. She has over fifteen years of experience in auditing and accounting. Ms. Wei is currently the partner of a certified public accounting firm in the PRC. Ms. Wei was first appointed as an independent non-executive Director in September 2004.

Ms. Au Fung Lan (歐鳳蘭), aged 44, is an independent non-executive Director. Ms. Au has over 12 years of experience in investment banking in Hong Kong. Ms. Au holds a bachelor degree of commerce from the University of Toronto in 1997. Ms. Au is currently the executive director of an investment bank in Hong Kong. Ms. Au was first appointed as an independent non-executive Director in June 2013.

SUPERVISORS

Supervisors nominated by Shareholders

Ms. Zhou Rui Juan (周瑞娟), aged 64, is a Supervisor and the chairman of the supervisory committee of the Company. She is also the supervisor of Shanghai Changmao. She graduated from Changzhou Light Industrial School (常州輕工學校) majoring in corporate management in 1988. Ms. Zhou passed the State Examination for Assistant Accountant in 1997. She was a financial accountant, the vice manager of the labour department and the director of the administrative department of the Company. Ms. Zhou was recognised as an activist of the labour union (工會積極分子) and an advanced worker (先進生產者) of the Company. She joined the Company in January 1993.

Mr. Lu A Xing (陸阿興), aged 50, is a Supervisor and a manager of the sales department of the Company. He obtained a diploma from Changzhou Chemical Worker's School (常州市化工職工學校) in 1988 and continued his studies at The Chinese Communist Party School of Jiangsu Province (中共江蘇省委黨校). Mr. Lu has over 20 years' experience in sales and marketing. Mr. Lu joined the Company in January 1993.

Supervisor nominated by employees

Mr. Zhang Jun Peng (張俊朋), aged 45, is a Supervisor and the chief officer of the concurrent production line of the Company and an engineer. He graduated from Jiangsu Institute of Petrochemical Technology (江蘇石油化工學院) in 1997 with a bachelor degree in chemical engineering. He was engaged in the continuous improvement and innovation of four-carbon series organic acid and obtained the Second Class Award of Process Innovation & Technological Invention (創新工藝技術發明二等獎) from China Petroleum and Chemical Industry Association (中國石油和化學工業協會) in 2004. Mr. Zhang was involved in various projects of the Company in respect of the improvement of production technology and is experienced in the production management of the Company. The concurrent production line led by Mr. Zhang won the championship of "the Cup of Safety and Health" ("安康杯"競賽優勝班組) in China in 2012 from the All-China Federation of Trade Unions (中華全國總工會) and the State Administration of Work Safety of the PRC (國家安全生產監督管理總局). He joined the Company in August 1997.

SUPERVISORS (Continued)

Independent Supervisors nominated by Shareholders

Prof. Jiang Yao Zhong (蔣耀忠), aged 82, is an independent Supervisor. He graduated from the department of chemistry of Peking University (北京大學) in 1957. He has been the vice president of the Chengdu branch of the Chinese Academy of Sciences (中國科學院成都分院) during 1990 to 1994. He was also the president of Chengdu Institute of Organic Chemistry, the Chinese Academy of Sciences (中國科學院成都有機化學研究所) during 1992 to 1997 and the scientific consultant of the Government of Sichuan Province from 1988 to 1998. He was a committee member of the Chemistry Society of China (中國化學會), a deputy director of the Committee of the Organic Chemistry (有機化學委員會), a chairman of the board of Sichuan Institute of Chemistry and Chemical Engineering (四川省化學化工學會), a member of the review panel of Department of Chemical Science of National Natural Science Foundation of China (國家自然科學基金委員會 化學部評審組成員) and a foreign member of the American Chemical Society and the chief editor of Synthetic Chemistry (合成化學) from 1998 to 2002. He is a researcher and an instructor of doctorate students in Organic Chemistry, the Chinese Academy of Sciences (中國科學院成都有 機化學研究所). Prof. Jiang was recognised as the Leader of Academy and Technology in Sichuan (四川省學術和技術帶頭人) in 1998 and awarded the Prize of Creation in Organic Synthesis by the Chemistry Society of China (中國化學會有機合成創造獎) in 2000. He also received the Second Class Award of National Natural Science Award (國家自然科學二等獎) in 2005, the Thomson Reuters Research Front Award in 2008, and Educator with Outstanding Contributions (傑出貢獻 教師) from the Graduate University of the Chinese Academy of Sciences (中國科學院研究生院) in 2008. Prof. Jiang was first appointed as an independent Supervisor in June 2004.

Mr. Geng Gang (耿剛), aged 58, is an independent Supervisor. He graduated from Jingsu Institute of Chemistry (江蘇化工學院) in 1982. He possesses over 20 years of experience in the field of chemical industry. Mr. Geng is recognised as a senior engineer by the Jiangsu Provincial Personnel Department (江蘇省人事廳). Mr. Geng is currently a deputy chief engineer, a director of laboratory and senior engineer of a chemical company and the vice chairman of the Technical Committee of China Cellulose Association (中國纖維素協會技術委員會). He obtained the Third Class Award of Jiangsu Science and Technology Progress (江蘇省科技進步三等獎) and the Second Class Award of Wuxi Science and Technology Progress (無錫市科技進步二等獎) for his research on the pilot-scale project of making viscose-styrene grafting fiber in 1990. He obtained the award of Wuxi Excellent Scientific Workers (無錫市優秀科技工作者稱號) in 1991 and the award of Wuxi Top Youth Expert (無錫市中青年專業技術拔尖人才) in 1992. Mr. Geng was first appointed as an independent Supervisor in June 2010.

SENIOR MANAGEMENT

Mr. Pan Chun (潘春), whose personal particulars are set out under the paragraph headed "Directors" in this section.

Mr. Wan Yi Dong (萬屹東), aged 45, is the deputy general manager of the Company. Mr. Wan is recognised as an engineer by the Bureau of Personel of Chang Zhou Municipality (常州市人事局). He graduated from Zhejiang University in 1996 with a bachelor degree in biochemistry. In 2004, he obtained a master degree in business administration from Nanjing University of Science and Technology. He joined the Company in August 1996. He was engaged in the technology advancement of bio-enzyme and immobilised enzyme technology and has been involved in various projects of the Company in respect of improvement in production technology and new technology on new products. Mr. Wan has published various professional articles in professional chemical magazines. He obtained various awards including the 常州市科技進步一等獎 (The First Class Award of Changzhou City Technological Achievement) in 2001 and 中國石油和化學工業協會科技進步二等獎 (The Second Class Award of Petrol Chemical Industry Technological Achievement in the PRC) in 2003. Mr. Wan joined the Company in August 1996.

Ms. Zhang Qin Ying (張琴英), aged 50, is the deputy general manager of the Company. She is also the supervisor of Lianyungang Changmao. She is a senior economist. She studied in Finance School of Changzhou (常州財經學校), specializing in financial management in 1999. She has also studied in The Chinese Communist Party School of Jiangsu Province in 2007, specializing in economic management. She has years of strong management experience in finance and labour union. She also serves as the chairman of the Union of Chemical Industry of Changzhou (常州市化工行業工會) and vice-chairman of the Union of Chemical and Light Industry in Changzhou (化輕產業工會). Ms. Zhang joined the Company in September 1993.

Ms. Wan, Pui Ling Alice (温珮玲) (CPA), aged 47, is the financial controller and company secretary of the Company. She has over twenty years of experience in accounting and financial management in Hong Kong and the PRC. Ms. Wan holds a bachelor degree in business administration and a master of science degree in finance from the Chinese University of Hong Kong, and is an associate member of the Hong Kong Institute of Certified Public Accountants. Ms. Wan joined the Company in June 2001.

Mr. Lu A Xing (陸阿興), whose personal particulars are set out under the paragraph headed "Supervisor" in this section.

Save as disclosed above, each of the Directors or Supervisors does not have any relationship with any directors, supervisors, senior management, management shareholders, substantial shareholders, or controlling shareholders of the Company (within the meaning of the Listing Rules).

The Company is committed to the maintaining of a high standard of corporate governance. The Company believes that good corporate governance provides a framework that is essential for effective management, a healthy corporate culture, successful business growth and enhancing shareholders' value.

COMPLIANCE WITH CODE PROVISIONS ON THE CODE ON CORPORATE GOVERNANCE PRACTICES

The Board is responsible for performing the corporate governance duties set out in the terms of reference in D.3.1 of the CG code.

Throughout the year ended 31 December 2018, the Company complied the code provisions of Corporate Governance Code and Corporate Governance Report as set out by the Stock Exchange in Appendix 14 to the Listing Rules, with the exception of Code Provisions A.6.7 (directors attending general meetings).

Code provision A.6.7 of CG Code stipulates that non-executive Directors and independent non-executive Directors should attend general meetings. Mr. Pan Chun, Mr. Zeng Xian Biao, Mr. Yu Xiao Ping, Mr. Wang Jian Ping, Prof. Ouyang Ping Kai, Prof. Yang Sheng Li, Ms. Wei Xin and Ms. Au Fung Lan were unable to attend the annual general meeting held on 18 May 2018, due to prior business commitments.

The Company's corporate governance structure includes the Board and the supervisory committee. The Company has also established three committees under the Board, namely the Remuneration Committee, the Audit Committee and the Nomination Committee. The corporate governance practices adopted by the Company are as follows:

THE BOARD

The major responsibilities of the Board include the formation of the Group's overall strategies, setting business plans and the supervision of the performance of the management. The Directors acknowledge their responsibility for preparing the financial statements on a going concern basis, with supporting assumptions or qualifications as necessary. The Board is also responsible for preparing a balanced, clear and understandable assessment of annual and interim reports, price-sensitive announcements and other disclosures required under the Listing Rules and other statutory requirements.

The Board comprises two executive Directors, namely, Mr. Rui Xin Sheng (Chairman) and Mr. Pan Chun (General Manager), four non-executive Directors, namely, Mr. Zeng Xian Biao, Mr. Yu Xiao Ping, Ms. Leng Yi Xin and Mr. Wang Jian Ping and four independent non-executive Directors, namely, Prof. Ouyang Ping Kai, Prof. Yang Sheng Li, Ms. Wei Xin and Ms. Au Fung Lan.

The roles of the chairman and chief executive (i.e. general manager) of the Company are separate and exercised by different individuals.

The Board meets regularly, and had met four times for the year ended 31 December 2018. Attendance of individual members of the Board meeting for the year ended 31 December 2018 is as follows:

	Name of Director	Attended/Eligible to attend
Executive Directors	Rui Xin Sheng (Chairman)	4/4
	Pan Chun (General Manager)	4/4
Non-executive Directors	Zeng Xian Biao	4/4
	Yu Xiao Ping	3/4
	Leng Yi Xin	4/4
	Wang Jian Ping	4/4
Independent Non-executive Directors	Ouyang Ping Kai	1/4
	Yang Sheng Li	0/4
	Wei Xin	4/4
	Au Fung Lan	3/4

Save that Ms. Leng Yi Xin is the wife of Mr. Rui Xin Sheng, each of the Directors is independent of other Directors.

Code of Conduct Regarding Securities Transactions by Directors

The Company has adopted the Model Code as its own code of conduct regarding securities transactions by Directors.

The spouse of Mr. Yu Xiao Ping ("Mr. Yu"), a non-executive Director, has overlooked the Model Code and purchased 220,000 H Shares of the Company at an average price of HKD0.8564 from the market on 1 February 2018 within the prohibition period (from 6 January 2018 to 16 March 2018) and has forgotten to first notify in writing the Company's chairman or a designated director and has not obtained a written acknowledgement as set out in Rule B.8 of the Model Code. Subsequently, Mr. Yu notified the Company the above transactions and acknowledged his breach of the Model Code. He undertook that he will comply with the required standards as set out in the Model Code in the future. Save as disclosed above, he does not have any record in breach of notification requirement for his dealings in the Company's shares since he became a Director in December 1992.

The Company has maintained an effective system in monitoring the director's dealings (including a notification mechanism) to ensure compliance with the Model Code. In particular, the Company has notified all Directors the above prohibition period on 12 December 2017. The Board is of the view that the guidelines and procedures for the director's dealings of shares in the Company are adequate and effective.

Keeping track of the Directors' dealings by the Company totally depends on whether the Directors take the initiative to ask for approval from the Company. In order to avoid similar incidents in the future, the Company reminded all the Directors at the Directors' meeting of the Company on 16 March 2018 the importance of complying with the Model Code in their dealings of the Company's shares and in submission of notifications. The Company will also emphasize and remind the Directors to avoid similar incidents in the prohibition period in the future. The Company also provides briefings to update and refresh the Directors' knowledge and skills on the latest developments regarding the Model Code, to ensure compliance and enhance their awareness of good corporate government practices.

The Company had also made specific enquiry of all Directors in relation to the compliance of the Model Code. Save for the above, the Company was not aware of any non-compliance with the Model Code for the year ended 31 December 2018.

Independent Non-executive Directors

The Company has received from each of the independent non-executive Directors an annual confirmation of his/her independence pursuant to Rule 3.13 of the Listing Rules and the Company still considers the independent non-executive Directors remained independent.

Continuous Professional Development

Directors' training is an ongoing process. During the year, Directors received regular updates and presentations on changes and developments to the Group's business and to environments in which the Group operates. All Directors are also encouraged to attend relevant training courses at the Company's expense. All Directors are required to provide the Company with his or her annual training record.

The Directors participated in the continuous professional developments in relation to regulatory update, the duties and responsibility of the Directors and the business of the Group in the following manner:

	Directors	Types of training
Executive Directors	Rui Xin Sheng	В, С
	Pan Chun	В, С
Non-executive Directors	Zeng Xian Biao	В
	Yu Xiao Ping	В
	Leng Yi Xin	В
	Wang Jian Ping	В
Independent non-executive Directors	Ouyang Ping Kai	В
	Yang Sheng Li	В
	Wei Xin	В
	Au Fung Lan	А, В

A: attending seminars provided by external parties

B: reading materials in relation to regulatory update

C: attending internal training sessions provided by the Company

BOARD COMMITTEES

Remuneration Committee

The Remuneration Committee was established to ensure there are formal and transparent procedures for developing and overseeing the Company's policies on the remuneration of its directors and senior management. The Remuneration Committee comprises four independent non-executive Directors, namely, Prof. Ouyang Ping Kai, Prof. Yang Sheng Li (chairman of the committee), Ms.Wei Xin and Ms. Au Fung Lan and an executive Director, Mr. Rui Xin Sheng. The Remuneration Committee makes recommendations to the Board on the remuneration packages of individual executive Directors and senior management. The Remuneration Committee held one meeting in 2018 to assess the performance of the executive Directors and review the policy for the remuneration of the Directors and how the Group complied with the staff incentive bonus scheme as stated below. The meeting attendance rate of individual members for the year ended 31 December 2018 was as follows:

Name of committee member

Attended/Eligible to attend

Rui Xin Sheng	1/1
Ouyang Ping Kai	1/1
Yang Sheng Li	1/1
Wei Xin	1/1
Au Fung Lan	1/1

The remunerations of Directors and senior management are based on the skill, knowledge and involvement in the Company's affair of each Director or senior management and are also determined with reference to the performance and profitability of the Group. The Company has formulated a staff incentive bonus scheme. Details of which is set out in the paragraph headed "Employees" under the section headed "Management Discussion and Analysis".

Audit Committee

The Company has established an audit committee with written terms of reference in compliance with the Listing Rules. The Audit Committee comprises four independent non-executive Directors, namely, Prof. Ouyang Ping Kai, Prof. Yang Sheng Li, Ms. Wei Xin (chairman of the committee) and Ms. Au Fung Lan.

The primary duties of the Audit Committee are to review and to provide supervision over the financial reporting process and internal control system of the Group, to review the Group's financial information and to review the audit plan, audit findings and independence of the auditors of the Company. The Audit Committee held six meetings for the year ended 31 December 2018, two of which were with the attendance of the external auditor. The meeting attendance rate of individual members for the year ended 31 December 2018 was as follows:

Name of committee member

Attended/Eligible to attend

Ouyang Ping Kai	6/6
Yang Sheng Li	6/6
Wei Xin	6/6
Au Fung Lan	6/6

Duties performed by the Audit Committee for the year were as follows:

- 1. made recommendations to the Board on the re-appointment of the external auditor, and to approve the remuneration and terms of engagement of the external auditor;
- 2. reviewed and monitored the external auditor's independence and objectivity and the effectiveness of the audit process in accordance with applicable standards, discussed with the external auditor the nature and scope of the audit and reporting obligations before the audit commences;
- 3. reviewed the Group's financial information, monitored the integrity of the Group's financial statements and the annual report and accounts and half-year report and reviewed significant financial reporting judgements contained in them. In reviewing these reports before submission to the Board, the Committee had focused particularly on:
 - (i) any changes in accounting policies and practices;
 - (ii) major judgmental areas;
 - (iii) significant adjustments resulting from audit (if any);
 - (iv) the going concern assumptions and any qualifications;
 - (v) compliance with accounting standards;
 - (vi) compliance with the Listing Rules and legal requirements in relation to financial reporting; and
 - (vii) consider any significant or unusual items that are, or may need to be, reflected in the report and accounts;

4. reviewed the Group's financial controls and internal controls, among others, by discussing the internal control system with the management to ensure that the management has performed its duty to have an effective internal control system; reviewed the Group's financial and accounting policies and practices; and reported to the Board on the matters in the CG Code.

Nomination Committee

The Nomination Committee was established to formulate and implement the nomination policy and Board Diversity Policy, nominate candidates of Directors for election by shareholders and to assess the independence of independent non-executive Directors. The Nomination Committee comprises four independent non-executive Directors, namely, Prof. Ouyang Ping Kai (chairman of the committee), Prof. Yang Sheng Li, Ms. Wei Xin and Ms. Au Fung Lan and an executive Director, Mr. Rui Xin Sheng.

The Nomination Committee held one meeting in 2018 to review the structure, size and composition of the Board and to assess the independence of independent non-executive Directors. The meeting attendance rate of individual members for the year ended 31 December 2018 was as follows:

Name of committee member

Attended/Eligible to attend

Rui Xin Sheng	1/1
Ouyang Ping Kai	1/1
Yang Sheng Li	1/1
Wei Xin	1/1
Au Fung Lan	1/1

POLICY FOR NOMINATION OF DIRECTORS

Procedures for Nomination and Appointments of Directors

Appointments of Directors, being individuals who are suitably qualified and expected to make positive contributions to the performance of the Board, are first considered by the Nomination Committee and then by the Board. Thereafter, all Directors are subject to election by shareholders at the shareholders' general meeting. A Director may serve consecutive terms if re-elected upon the expiration of the terms.

Each of Mr. Rui Xin Sheng and Mr. Pan Chun has entered into a service agreement with the Company. All the other Directors have not entered into any service agreement with the Company. The terms of each Director is not more than three years and will be expired on 17 June 2019.

Nomination of Candidates for Re-election of Directors

The terms of the sixth session of the Directors will expire on 17 June 2019. Except for Prof. Yang Sheng Li who decided not to stand for re-election, all retiring Directors are eligible and will offer themselves for re-election at the forthcoming AGM. Prof. Yang Sheng Li has confirmed that he has no disagreement with the Board or supervisory committee of the Company and nothing relating to the affairs of the Company needed to be brought to the attention of the shareholders of the Company.

On 8 March 2019, the Nomination Committee, having reviewed the Board's composition, nominated all the existing Directors (except for Prof. Yang Sheng Li) to the Board for it to recommend to Shareholders for re-election at the forthcoming AGM. The nominations were made in accordance with the Nomination Policy and the objective criteria (including without but not limited to skills, regional and industry experience, background, race, gender and length of service), with due regard for the benefits of diversity, as set out under the Board Diversity Policy. The Nomination Committee has also taken into account the Board performance evaluation for the past three years, confirmed that all the existing Directors continue to contribute effectively and are committed to their roles. Although Prof. Ouyang Ping Kai and Ms. Wei Xin have served as independent non-executive Directors for more than 9 years, they meet the independence factors set out in Rule 3.13 of the Listing Rules and are not involved in the daily management of the Company, nor in any relationships or circumstances which would interfere with the exercise of their independent judgment. In addition, they continue to demonstrate the attributes of independent non-executive directors and there is no evidence that their tenure have had any impact on their independence. Taking into account the above, the Nomination Committee is of the opinion that Prof. Ouyang Ping Kai and Ms. Wei Xin remain independent notwithstanding the length of their service and it believes that their valuable knowledge and experience in the Group's business and their general business acumen continue to generate significant contribution to the Company. Accordingly, the Nomination Committee, in accordance with the Nomination Policy and Board Diversity Policy, nominated all the existing Directors to stand for election by Shareholders at the forthcoming Annual General Meeting. On 12 March 2019, the said nominations were accepted by the Board with each candidate abstaining from voting on the proposition of himself for election by Shareholders. All the candidates for re-election of Directors do not have any service contracts with any member of the Group that are not determinable by the Group within 1 year without compensation (other than statutory compensation), and their particulars are set out in the "Information on the Candidates for Re-election of Directors and Supervisors" in the circular in relation to the Company's forthcoming Annual General Meeting.

Board Diversity Policy


The Group has adopted a board diversity policy (the "Board Diversity Policy"). A summary, together with the measurable objectives set for implementing this policy, and the progress made towards achieving those objectives are disclosed as below.

Summary of the Board Diversity Policy and Measurable Objectives

The Company recognises and embraces the benefits of diversity in the Board. The Company believes that a diversity of perspectives can be achieved through consideration of a number of factors, including but not limited to skills, regional and industry experience, background, race, gender and other qualities. In performing its perspective on diversity, the Company will also take into account factors based on its own business model and specific needs from time to time. The Company endeavours to ensure that its Board has the appropriate balance of skills, experience and diversity of perspectives that are required to support the execution of its business strategies and in order for the Board to be effective. The ultimate decision will be based on merit and contribution that the selected candidates will bring to the Board.

Implementation and Monitoring

The Nomination Committee reviewed the Board's composition under diversified perspectives, and monitored the implementation of the Board Diversity Policy annually. As at the date of this report, the Board's composition under major diversified perspectives was summarized as follows:



THE SUPERVISORY COMMITTEE

The supervisory committee is accountable to the general meeting. The primary responsibilities of the supervisory committee include the monitoring of whether the Directors and senior management have, in the performance of their duties, acted in contravention of any laws, administrative regulations, the Articles of Association of the Company or the resolutions passed at general meetings; and the reviewing of the Company's financial information. Supervisors can attend the Board meetings.

The supervisory committee comprises two supervisors nominated by shareholders, Ms. Zhou Rui Juan and Mr. Lu A Xing, a supervisor nominated by employees, Mr. Zhang Jun Peng and two independent supervisors nominated by shareholders, Prof. Jiang Yao Zhong and Mr. Geng Gang. Each of Ms. Zhou Rui Juan, Mr. Lu A Xing, and Mr. Zhang Jun Peng has entered into a service agreement with the Company. Prof. Jiang Yao Zhong and Mr. Geng Gang have not entered into any service agreement with the Company. The terms of each supervisor is not more than three years and will be expired on 17 June 2019.

The supervisory committee held two meetings for the year ended 31 December 2018 with attendance rate of 100%.

COMPANY SECRETARY

The Company Secretary, Ms. Wan, Pui Ling Alice, is responsible for facilitating the Board process, as well as communications among Board members, with shareholders and management. She reports to the Board Chairman and the general manager of the Company. The Company Secretary's biography is set out in the "Profiles of Directors, Supervisors and Senior Management" section of this Annual Report. During 2018, the Company Secretary undertook over 15 hours of professional training to update her skills and knowledge.

DIRECTORS' RESPONSIBILITY FOR THE FINANCIAL STATEMENTS

The Directors acknowledge their responsibility for preparing the financial statements for the year ended 31 December 2018, which give a true and fair view of the state of affairs of the Group at that date and of the Group's profit and cash flows for the year then ended and are properly prepared on the going concern basis in accordance with the statutory requirements and applicable accounting standards.

The statement of the Auditor of the Company about its reporting responsibilities on the consolidated financial statements of the Company is set out in the Independent Auditor's Report on pages 60 to 65.

RISK MANAGEMENT AND INTERNAL CONTROL

The Board is responsible for ensuring sound and effective risk management and internal control systems to safeguard the shareholders' interests and the Company's assets. The risk management and internal control systems are designed to manage rather than eliminate the risk of failure to achieve business objectives, and can only provide reasonable and not absolute assurance against material misstatement or loss.

The successful management of risks is essential for the long-term growth and sustainability of the Group's business. The Board is responsible for setting strategies, business objectives and risk appetite as well as ensuring a review of effectiveness of the risk management and internal control systems, and oversees management in the design, implementation and monitoring of the risk management and internal control systems. In 2018, the management have provided a confirmation to the Board on the effectiveness of such systems. The Board also reviewed the Group's risk management and internal control systems, which the Board considers to be adequate and effective in 2018. The level of resources, staff qualifications and experience, training programs and budget of the Company's internal audit and accounting and financial reporting functions were assessed and considered adequate.

A management committee has been established to ensure that significant risks are identified; assessed by considering the impacts and likelihoods of their occurrence; and effectively managed by identifying suitable controls and countermeasures, and assessing the cost effectiveness of the mitigating actions proposed. With the assistance of the this committee, the Board continuously monitors the company's risk management framework, reviews the Group's significant risks and emerging risks, and conducts an annual review of the effectiveness of the risk management system. The Board determines the nature and extent of significant risks it is willing to take in achieving the strategic objectives of the Group. Each department of the Group is responsible for identifying its own risks and designing, implementing and monitoring the relevant risk management and internal control systems. The process involves the maintenance of risk register setting out the particulars of material risks together with the control measures as reported by significant departments of the Group. It ensures that significant risks are considered by the Board in determining their risk appetite.

A risk management policy has been adopted to serve as a guideline for risk management and internal control systems.

Internal audit

Internal control system shall allow monitoring of the Company's overall financial position; safeguard its assets against major losses and misappropriation; provide reasonable assurance against material fraud and errors; and efficiently monitor and correct non-compliances.

The Company does not have an internal audit department but has engaged an external professional party to perform internal audits to evaluate the proper functioning of the internal control systems for the year ended 31 December 2018. It is intended to carry out this evaluation process on an ongoing basis. The Audit Committee, after reviewing and considering the management findings from the internal control report, then reported to the Board of the Company and confirmed to the Board that the internal control systems are effective and adequate.

Inside Information Policy

The Board approved and adopted an Inside Information Policy which contains the guidelines to the Directors, officers and all relevant employees (likely possessing the unpublished inside information) of the Group to ensure that the inside information of the Group is to be disseminated to public in equal and timely manner in accordance with the applicable laws and regulations. Such procedures include, among others, notification of regular blackout period and securities dealing restrictions to relevant Directors and employees, identification of project by code name and dissemination of information to stated purpose and on a need-to-know basis have been implemented by the Group to guard against possible mishandling of inside information within the Group.

AUDITOR'S REMUNERATION

PricewaterhouseCoopers have been re-appointed as the Company's international external auditor by the shareholders at the 2018 annual general meeting. They are primarily responsible for providing audit services in connection with the Company's annual financial statements and internal control review.

During the year, the remuneration to the external auditor in Rmb equivalent is as follow:

	2018	2017
	Rmb′000	Rmb′000
Auditors' remuneration		
– Audit Service	1,367	1,261
 Non-audit Service 	_	114

DIVIDEND POLICY

The Company's policy is to provide dividends to shareholders which is linked to the underlying performance of business. The Board considers that it would be prudent and appropriate to target a pay-out ratio of 30% to 70% per cent of the Group's consolidated net profit attributable to the equity holders of the Company. The actual dividend pay-out ratio, however, may cause some deviation from the target, depending on the cash flows and future funding requirements of the Company.

SHAREHOLDERS' RIGHTS

Convening an extraordinary general meeting

Pursuant to Article 61 of the Articles and Associations of the Company, shareholder(s) holding 10% or more of the Company's issued capital that carry voting rights request(s) in writing for the convening of an extraordinary general meeting, the board of Directors shall convene an extraordinary general meeting within 2 months.

Procedures for putting forward proposals at shareholders' meeting

Pursuant to Article 63 of the Articles and Associations of the Company, when the Company convenes a shareholders' annual general meeting, shareholder(s) holding 5% or more of the total shares carrying voting rights of the Company are entitled to propose new matters in writing to be considered, and the Company shall include in the agenda of that meeting those matters contained in the proposal which are within the scope of the duties of the general meeting provided that the proposal is delivered to the Company within 30 days from the issue of the notice of the meeting.

Procedures for nominating a new Director

Pursuant to Article 97 of the Articles and Associations of the Company, a notice of the intention to propose a person for election as Director and the written notice by such candidate of his/her willingness to accept the nomination shall be given to the Company no less than seven days. The minimum seven-day period of lodgement by the shareholders of notice to nominate a Director shall commence no earlier than the date after the despatch of the notice of the meeting appointed for such election and end no later than seven days before the date of such meeting.

Communications with Shareholders

The Board always welcome Shareholders' and other stakeholder's questions and concerns relating to the Group's management and governance. Shareholders and other stakeholders may at any time send their enquiries and concerns to the Board by addressing them to Company Secretary by post. The address is Room 54, 5th Floor, New Henry House, 10 Ice House Street, Central, Hong Kong.

Articles of Association

The Company has revised the Articles of Association to the Company once during the year ended 31 December 2018. For details of the amendments, please refer to the circular issued by the Company dated 28 March 2018.

By order of the Board

Rui Xin Sheng Chairman

The PRC, 12 March 2019

ENVIRONMENTAL AND SOCIAL REPORT

ENVIRONMENTAL POLICIES AND PERFORMANCE

The Board is well aware of the importance of environmental protection on the Group's sustainability and stable development, and at the same time strives to improve product quality while achieving the best balance between cost control and environmental protection. The Group has established an environmental management system based on the actual situation and its factory in Changzhou obtained ISO14001 certification. The Group aims to be a resource-saving and environment-friendly enterprise with low energy and resources consumption and low level of discharge on wastages. The Group promotes clean production, prevents pollution and reduces the risk of environmental accidents. The Group's environment protection department dedicates to strengthen its environmental protection, actively implements environmental policies, vigorously carries out environmental management, and takes energy-saving measures to achieve reduction on pollution. At the same time, the Group also has a full-time environmental protection workshop to treat the wastewater of each production line in a centralised manner and discharges it into the sewage treatment company of the industrial area. In addition, the environmental protection department conducts centralised management and treatment of solid waste and hazardous waste in the production lines, and the production tail gas is collected and put into regenerative thermal oxidizer for incineration treatment. Therefore, the Group's business activities have no significant impact on the environment and natural resources.

All of the Group's production is conducted in Mainland China. The Group is required to comply with the environmental protection laws and regulations promulgated by the national and local governments of the PRC. Some of these regulations govern the level of fees payable to government entities providing environmental protection services and the prescribed standards relating to the discharge of solid wastes, effluent and gases. The Group's production technology enables the Group to effectively control the pollution caused by the production process. The Group has installed waste disposal facilities to reduce waste discharge. The Group did not aware of any violations of the laws and regulations on environmental protection in 2018.

The following discussion and information on the environment are the combined information of the Group's factories in Changzhou and Lianyungang.

I. Emissions

As the Group is mainly engaged in production, the following discussion on emissions is mainly related to the emissions from production.

(1) Greenhouse gases emission

The Group has carbon dioxide and methane emissions. There are no requirements under the PRC rules and regulations to measure these greenhouse gases. In order to reduce costs and emissions, the Group started in 2018 using butane to replace benzene as a raw material for production. Using of butane to produce maleic anhydride will reduce carbon dioxide emissions. It is cleaner and more environmentally friendly and in line with the international trend of food additive production.

ENVIRONMENTAL AND SOCIAL REPORT

The Group's indirect greenhouse emissions are mainly from electricity and steam consumption. In order to reduce steam consumption, the Group recycles the steam output from the maleic anhydride production line. This not only can reduce greenhouse gas emissions, but also reduce production costs. In order to reduce emissions, the Group is committed to ensure the efficient operation of the equipment and the implementation of cleaner production. Hazardous and non-hazardous wastes are mainly disposed of by qualified waste disposal companies for incineration or recycling.

(2) Sewage and noise

The Group employs independent environmental monitoring companies to measure sewage water quality and noise emissions annually for its Changzhou and Lianyungang plants. The emissions in 2018 are within the limits set by the national standards.

Key Performance Indicators

	2018	2017
Amount of waste water in total (in tonnes)	451,557	370,614
Amount of waste water - Per unit of output		
(in tonnes/tonne)	13.92	9.05
Exhaust gas in total (in tonnes)	17.94	0.05
Exhaust gas – Per unit of output (in tonnes/tonne)	0.001	0.001
Greenhouse gas emissions in total (in tonnes) (note)	99,940	113,632
Greenhouse gas emissions in total – Per unit of output		
(in tonnes/tonne) (note)	3.08	2.78
Hazardous waste produced in total (in tonnes)	1,787	1,043
Hazardous waste produced – Per unit of output		
(in tonnes/tonne)	0.06	0.03
Non-hazardous waste produced in total (in tonnes)	1,548	2,207
Non-hazardous waste produced – Per unit of output		
(in tonnes/tonne)	0.05	0.05

Note:

The Group converted its greenhouse gas emissions according to GBT32151.10-2015, "Requirements for the Greenhouse Gas Emissions Accounting and Reporting – Part 10: Chemical Production Enterprises (溫室氣體排放核算與報告要求一第10部分:化工生產企業)". It is the sum of direct and indirect greenhouse gas emissions from the Changzhou plant and Lianyungang plant.

The Group's direct greenhouse gas emissions related to n-butane, the raw material of Changzhou plant and Lianyungang plant. The amount of greenhouse gas converted the steam sold by the Group has been deducted from the total direct greenhouse gas emissions. When calculating the amount of direct greenhouse gas converted from steam, the emission factor for heat consumption is calculated based on the "2010 Shanghai Energy Balance Sheet and the GHG inventory compilation data (上海市2010年能源平衡表和温室氣體清單)".

The Group's indirect greenhouse gas emissions related to the emissions from purchase of electricity and heat by the two plants. The calculation of electricity emission factors used from electricity purchased is based on the latest data released by National Development and Reform Commission which the factor of East China Regional Power Grid (EFgrid, BM, y(tCO₂/MWh)) adopted in the calculation is 0.4923 (2017: 0.5483). The calculation of the heat-generating emissions factors of the thermal consumption purchased is based on the "2010 Shanghai Energy Balance Sheet and the GHG inventory compilation data" and the value taken is 0.11t CO₂/GJ.

II. Use of Resources

The Group is committed to reducing energy consumption. In the production process, the Group needs to use energy, including water, electricity and steam.

(1) Water

The Changzhou plant of the Group is accredited as a water-saving enterprise in Changzhou City. The Group adopted the municipal policies and plans to use water efficiently and save water usage. The Group clearly understood these directions and adopted effective measures. The effect is obvious in recent years with gradual reduction in water consumption per unit of product. The Group improved the production equipment, used water-saving technology to achieve the rational use of water resources, the Group has effectively controlled the discharge of recycled water, backwashed water for centralised reuse to achieve water-saving effect.

The Changzhou plant of the Group has passed the assessment and obtained "Water Balance Test Certificate (水量平衡測試合格證)" which indicated that the Group's water consumption level is reasonable. The Group uses water from local water companies and there is no any issue in sourcing water.

(2) Electricity

The Group has effectively used of power resources. The power supply bureau adopts the policy of "top, peak, valley and flat" charging policy, that is, different charges in different periods. Unit charges is the highest in the 'top period', and lowest at the 'valley period'. The Group actively cooperated with the relevant policies to raise the proportion of electricity consumption in the 'valley and flat period' to reduce the production costs.

(3) Steam

There are two sources of steam, one is purchase from third parties and the other is recovery and recycling of steam generated during the production process. Recycling of steam helps to reduce energy consumption and production costs. The steam generated during production in Lianyungang plant, not only enough to recycle for its own use, there is excess steam produced for selling to the nearby factory. It helps both to reduce steam emissions, and also bring economic benefits to the Group. In addition, in terms of reducing energy consumption, the Group uses recycled steam to drive turbine to drive ventilator in production, reducing costs and increasing efficiency while achieving energy conservation and environmental protection.

(4) Packaging materials

There are different types of packaging materials. Packaging materials only accounted for a very small portion production costs. In 2018, packaging materials only accounted for less than 2% of the cost of production.

Key Performance Indicators

	2018	2017
Electricity consumption in total (in kwh)	43,289,057	59,498,280
Electricity consumption – Per unit of output		
(in kwh/tonne)	1,334	1,454
Steam consumption in total (sourcing from outside		
and self production) (in tonnes)	296,330	329,582
Steam consumption (sourcing from outside and self		
production) – Per unit of output (in tonnes/tonne)	9.1	8.1
Steam consumption in total (sourcing from outside)		
(in tonnes)	169,657	209,398
Steam consumption (sourcing from outside)		
Per unit of output (in tonnes/tonne)	5.2	5.1
Water consumption in total (in tonnes)	636,216	998,837
Water consumption – Per unit of output (in tonnes/tonne)	19.6	24.4

SOCIAL

(I) Employment and Labour Practices

The Group's principle is people-oriented. It continuously improves the working environment and remuneration and to provide a broad developmental platform for the employees to display their individual talents. It has resolutely implemented the relevant national and local government laws and regulations in relation to employment. The Group has established a fine social accountability system, covering all aspects of employment regulations and social welfare. The Group provides its staff with a safe working environment by implementing the safety standard management and has accredited as the national "Second Grade Enterprise of Work Safety Standardisation" (安全生產標準化二級企業).

The Group attaches great importance to staff training. The Group provides trainings to staff which are relevant to their duties, including management, regulatory update, environment protection, food safety, team building, etc. The Group also encourages the employees to attend different kinds of colleges and universities courses and trainings to strengthen their academic qualifications which are related to their work duties by providing subsidies to them.

For safety training, management personnel involved in the production have to participate in safety training and pass the assessment by Changzhou production safety publicity and education centres. The Group's safety director and safety department organise trainings on relevant laws and regulations, safety knowledge, and enterprise management system for the person in charge of safety and head of different production lines each month. The safety department also organises training for staff working in the production lines on safety production and technology operation, techniques on operation of new equipment before commencement of new projects and production with new production technologies.

In addition, pay raise and benefits for employees every year are based on their performance. The Group organised different social activities every year, so that the employees in various positions of different departments of the Group can increase communication and strengthen interaction.

The Group strictly complies with the State Council's regulation on "Provisions on the Prohibition of Using Child Labour" on executing the employment standards, and has established recruitment procedures and measures to ensure that child labour is not employed. The vast majority of the Group's employees are Chinese. The Group is not aware of any violation of employment and labour laws and regulations nor any violation of child labour provisions in 2018.

The followings are key performance indicators in relation to the Group's employment and labour practices:

key performance mulcators	2018	2017	2016
Number of employees (by gender)			
Male	326	409	421
Female	153	168	174
Number of employees (by employment type)			
Management	68	70	62
Production	320	406	426
Sales	26	29	31
Research and development	65	72	76
Number of employees (by age group)			
30 or under	161	251	293
31-50	282	291	269
Over 50	36	35	33
Training			
Training expenses	Rmb186,000	Rmb158,000	Rmb217,000
Percentage of employees trained Average training hours completed per	98%	98%	91%
employee	70	72	76

(II) Operating Practices

(1) Supply Chain Management

The Group has more than 100 qualified suppliers. To become qualified suppliers, their samples have to pass the examination, the trial production by the Group and suppliers' assessments. Performance of all suppliers for the previous year would be evaluated at the beginning of each year and they can continue as the Group's suppliers after passing the evaluation. Evaluation of new suppliers and subcontractors includes their commitment to social responsibility and performance. The Group has a procurement management systems and has developed a series of procurement control procedures for strict selection of suppliers and control the procurement process. Procurement staff regularly visits suppliers to maintain close contacts and good cooperation relations with them. The vast majority of the Group's suppliers are located in mainland China.

(2) Product Liability

After 20 years of accumulation, the Group's customers are all over the world. The Group has always focused on maintaining customer relationships. In recent years, the Group has continued to strengthen direct sales to end-users with a closer and long-term customer relation. The Group strictly controls its product safety and quality to maintain quality leadership and ensure customer satisfaction. The Group has met the highest standards in the food safety systems FSSC22000 and quality management system ISO9001. The Group conducts customer satisfaction survey each year to obtain customers' feedback and understand their requirements, as well as serve as an objective assessment to the Group. Reports show that the Group's customers were satisfied in 2018.

The Group has standard procedures to handle customer complaints. The Group has been focusing on product quality, and continuously improving the process to ensure product quality and strengthen brand management to meet potential complaints and ensure proper quality delivery.

The Group has a trademark management system and business ethics code control procedures, and strictly complies with the laws and regulations for protection of intellectual properties.

The Group has inspection and test control procedures to test the semi-finished products or finished products item by item. Standard procedures are in place to deal with each qualified or non-qualified products. There is a "certificate of analysis" for each finished product to facilitate product traceability. In case a product recall is triggered, the Group initiates a recall procedure, analyses the extent of the food hazard and classifies it, re-examines the products if necessary and makes a recall if needed based on the results of the analysis or examination. The Group would also record the number of products recalled to ensure that unsafe batch of products are fully and promptly recalled and are appropriately processed in accordance with the procedures for handling recalled products. In 2018, the Group has not recalled any sold or shipped products due to safety and health reasons.

The Group also endeavors to ensure the proper use of customer information. The Group has complied with the relevant national laws and regulations and the Group's internal business ethics control procedures when collecting, processing and using such information in the course of business.

(3) Anti-corruption

The Group has anti-corruption control procedures issued to all employees, and has mechanisms for employees to report problems found. The Group has management system and measures on fund management to prevent money laundering. The Group conducts an internal audit of social responsibilities every year to examine whether there are any bribery, extortion or fraud.

There was no significant risk associated with bribery identified in 2018. There was no concluded legal cases regarding corrupt practices brought against the Group or its employees. There were no confirmed incidents of contract termination or non-renewal of contract with business partners due to embezzlement during the year. During the year, the Group did not receive any reports in relation to corruption.

(III) Society

In terms of participating in social investment, the Group has made a Rmb140,000 donation to the Changzhou Charity Association in 2018.

The Directors have pleasure in submitting their report together with the audited consolidated financial statements for the year ended 31 December 2018.

PRINCIPAL ACTIVITIES AND GEOGRAPHICAL ANALYSIS OF OPERATIONS

The principal activities of the Company are the production and sale of organic acids products. The activities of the subsidiaries are set out in note 18 to the consolidated financial statements.

An analysis of the Group's revenue for the year by geographic segments is set out in note 5 to the consolidated financial statements.

RESULTS AND APPROPRIATIONS

The results of the Group for the year are set out in the consolidated statement of comprehensive income on page 66.

No interim dividend was declared during the year (2017: Nil). The Directors recommend the payment of a final dividend of Rmb0.05 (2017: Nil) (inclusive of tax) per share for the year ended 31 December 2018 totalling approximately Rmb26,485,000 (2017: Nil).

DONATIONS

Charitable and other donations made by the Group during the year amounted to Rmb140,000 (2017: Rmb190,000).

SHARE ISSUED IN THE YEAR

Details of the shares issued by the Company in the year ended 31 December 2018 are set out in note 24 to the consolidated financial statements.

DISTRIBUTABLE RESERVES

As at 31 December 2018, the distributable reserves of the Company were approximately Rmb416,392,000 (2017: Rmb350,946,000) as reported in the statutory financial statements prepared in accordance with the PRC Generally Accepted Accounting Principles.

PRE-EMPTIVE RIGHTS

There is no provision for pre-emptive rights under the Articles of Association of the Company or the laws of the PRC, being the jurisdiction in which the Company was established, which provides the existing shareholders with pre-emptive rights to purchase new shares in any new issue of the Company according to their respective proportion of shareholding.

SUMMARY FINANCIAL INFORMATION

A summary of the published results and assets and liabilities of the Group for the last five years is set out on page 134 of the annual report.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

Neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities for the year ended 31 December 2018.

DIRECTORS AND SUPERVISORS

The Directors and Supervisors during the year were:

Executive Directors

Mr. Rui Xin Sheng (Chairman)

Mr. Pan Chun

Non-executive Directors

Mr. Zeng Xian Biao

Mr. Yu Xiao Ping

Ms. Leng Yi Xin

Mr. Wang Jian Ping

Independent non-executive Directors

Prof. Ouyang Ping Kai

Prof. Yang Sheng Li

Ms. Wei Xin

Ms. Au Fung Lan

Supervisors nominated by shareholders

Ms. Zhou Rui Juan

Mr. Lu A Xing

Supervisor nominated by employees

Mr. Zhang Jun Peng

Independent Supervisors nominated by shareholders

Prof. Jiang Yao Zhong

Mr. Geng Gang

DIRECTORS AND SUPERVISORS (Continued)

The terms of each of the Directors and Supervisors will be expired on 17 June 2019. In accordance with Article 97, 116 and 117 of the Company's Articles of Association, Directors and Supervisors nominated by shareholders shall be elected at the shareholders' general meeting for a term of three years. Supervisor who is a representative of employees shall be elected by the employees of the Company for a term of three years. A Director or Supervisor may serve consecutive terms if re-elected upon the expiration of the terms.

DIRECTORS' AND SUPERVISORS' SERVICE CONTRACTS

Each of Mr. Rui Xin Sheng, Mr. Pan Chun, Ms. Zhou Rui Juan, Mr. Lu A Xing, and Mr. Zhang Jun Peng has entered into a service agreement with the Company. All the other Directors and Supervisors have not entered into any service agreement with the Company.

Save as above, no Director or Supervisor who is proposed for re-election at the forthcoming Annual General Meeting has a service contract with the Company which is not determinable within one year without payment of compensation other than statutory compensation.

DIRECTORS' AND SUPERVISORS' MATERIAL INTEREST IN TRANSACTIONS, ARRANGEMENTS AND CONTRACTS THAT ARE SIGNIFICANT IN RELATION TO THE COMPANY'S BUSINESS

No transactions, arrangements and contracts of significance in relation to the Group's business to which the Company or its subsidiaries was a party and in which a Director, a Supervisor and a connected party of a Director or a Supervisor had a material interest, whether directly or indirectly, subsisted at the end of the year or at any time during the year.

INTERESTS AND SHORT POSITIONS OF THE DIRECTORS, SUPERVISORS OR CHIEF EXECUTIVES IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY SPECIFIED UNDERTAKING OF THE COMPANY OR ANY OTHER ASSOCIATED CORPORATIONS

As at 31 December 2018, the interests (including interests in shares and short positions) of the Directors, Supervisors or chief executives of the Company in the shares, underlying shares and debentures of the Company or any specified undertaking of the Company or any other associated corporations (within the meaning of Part XV of the SFO), which were notified to the Company and the Stock Exchange pursuant to: (a) Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which each of them is taken or deemed to have taken under such provisions of the SFO); or (b) Section 352 of the SFO to be entered in the register referred to in that section; or (c) Appendix 10 of the Listing Rules relating to securities transactions by Directors; or (d) the Hong Kong Companies Ordinance (Cap. 622), to be notified to the Company and the Stock Exchange, were as follows:

Long positions in shares:

Director	Capacity	Number of Domestic Shares	Approximate percentage shareholding in the Domestic Shares (Note (I))	Number of Foreign Shares	Approximate percentage shareholding in the Foreign Shares (Note (m))	Number of H Shares	Approximate percentage shareholding in the H Shares (Note (n))
Mr. Rui Xin Sheng	Interest of spouse, interest of controlled corporation, trustee (other than a bare trustee) and custodian (Note (a))	2,500,000	100%	135,000,000	39.30%	2,672,000	1.45%
Ms. Leng Yi Xin	Beneficial owner, interest of spouse and interest of controlled corporation (Note (b))	2,500,000	100%	135,000,000	39.30%	2,672,000	1.45%
Mr. Pan Chun	(Note (c))	-	-	(Note (c))	(Note (c))	-	-
Mr. Zeng Xian Biao	(Note (d))	-	-	(Note (d))	(Note (d))	-	-
Mr. Yu Xiao Ping	Interest of spouse and interest of controlled corporation (Note (e))	-	-	66,000,000	19.21%	2,620,000	1.43%

INTERESTS AND SHORT POSITIONS OF THE DIRECTORS, SUPERVISORS OR CHIEF EXECUTIVES IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY SPECIFIED UNDERTAKING OF THE COMPANY OR ANY OTHER ASSOCIATED CORPORATIONS (Continued)

Long positions in shares: (Continued)

Di v		Number of Domestic	the Domestic	Number of Foreign	Approximate percentage shareholding in the Foreign	Number of	Approximate percentage shareholding in the
Director	Capacity	Shares	Shares (Note (l))	Shares	Shares (Note (m))	H Shares	H Shares (Note (n))
Prof. Ouyang Ping Kai	(Note (f))	-	-	(Note (f))	(Note (f))	-	-
Prof. Yang Sheng Li	(Note (g))	-	-	(Note (g))	(Note (g))	-	-
Supervisor							
Ms. Zhou Rui Juan	(Note (h))	-	-	(Note (h))	(Note (h))	-	-
Mr. Lu A Xing	(Note (i))	-	-	(Note (i))	(Note (i))	-	-
Mr. Zhang Jun Peng	(Note (j))	-	-	(Note (j))	(Note (j))	-	-
Prof. Jiang Yao Zhong	(Note (k))	-	-	(Note (k))	(Note (k))	-	-

Notes:

(a) The 135,000,000 Foreign Shares are held by HK Xinsheng Ltd and the 2,500,000 Domestic Shares are held by Changzhou Xinsheng, 2,620,000 H Shares are held by Bonus Sky Investments Limited and 52,000 H Shares are held by Ms. Leng Yi Xin, spouse of Mr. Rui. The issued share capital in HK Xinsheng Ltd comprises 170,000 Class "A" shares and 100,000 Class "B" shares. Mr. Rui is the registered holder and beneficial owner of 96,500 Class "A" shares. He is also the registered holder of 53,000 Class "B" shares and holds such shares as trustee in respect of a discretionary trust for the group of persons who made contribution to the Company or who from time to time make contribution to the Company. Mr. Rui is the registered holder and beneficial owner of 70% of the registered capital of Changzhou Xinsheng. Mr. Rui is the beneficial owner of 100% of the issued share capital of Bonus Sky Investments Limited. Ms. Leng, a Director and the spouse of Mr. Rui, is also interested in HK Xinsheng Ltd and Changzhou Xinsheng, details of which are set out in Note (b) below.

INTERESTS AND SHORT POSITIONS OF THE DIRECTORS, SUPERVISORS OR CHIEF EXECUTIVES IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY SPECIFIED UNDERTAKING OF THE COMPANY OR ANY OTHER ASSOCIATED CORPORATIONS (Continued)

- (b) Ms. Leng is the registered holder and beneficial owner of 73,500 Class "A" shares in HK Xinsheng Ltd, which is the registered holder and beneficial owner of 135,000,000 Foreign Shares. The issued share capital in HK Xinsheng Ltd comprises 170,000 Class "A" shares and 100,000 Class "B" shares. Ms. Leng is the registered holder and beneficial owner of 30% of the registered capital of Changzhou Xinsheng, which is the registered holder and beneficial owner of 2,500,000 Domestic Shares. Mr. Leng is also the registered holder and beneficial owner of 52,000 H Shares. Mr. Rui, a Director and the spouse of Ms. Leng, is also interested in HK Xinsheng Ltd, Changzhou Xinsheng and Bonus Sky Investments Limited, details of which are set out in Note (a) above.
- (c) Mr. Pan is the registered holder and beneficial owner of 2,000 Class "B" shares in HK Xinsheng Ltd, which is the registered holder and beneficial owner of 135,000,000 Foreign Shares. The issued share capital in HK Xinsheng Ltd comprises 170,000 Class "A" shares and 100,000 Class "B" shares. He is also the registered holder and beneficial owner of 200,000 shares in HK Biochem Ltd, which is the registered holder and beneficial owner of 67,500,000 Foreign Shares. The total number of issued shares in HK Biochem Ltd is 6,750,000 shares.
- (d) Mr. Zeng is the registered holder and beneficial owner of 380,000 shares in HK Biochem Ltd, which is the registered holder and beneficial owner of 67,500,000 Foreign Shares. The total number of issued shares in HK Biochem Ltd is 6,750,000 shares. Mr. Zeng is also the registered holder and beneficial owner of 2,000 Class "B" shares in HK Xinsheng Ltd, which is the registered holder and beneficial owner of 135,000,000 Foreign Shares. The issued share capital in HK Xinsheng Ltd comprises 170,000 Class "A" shares and 100,000 Class "B" shares.
- (e) Mr. Yu and his wife (who is not a Director) taken together are interested in the entire issued capital of Jomo Limited which is the registered holder and beneficial owner of 66,000,000 Foreign Shares. Mr. Yu's wife, Ms. Lam Mau, is also the beneficial owner of 2,620,000 H Shares.
- (f) Prof. Ouyang is the registered holder and beneficial owner of 4,000 Class "B" shares in HK Xinsheng Ltd, which is the registered holder and beneficial owner of 135,000,000 Foreign Shares. The issued share capital in HK Xinsheng Ltd comprises 170,000 Class "A" shares and 100,000 Class "B" shares.
- (g) Prof. Yang is the registered holder and beneficial owner of 2,000 Class "B" shares in HK Xinsheng Ltd, which is the registered holder and beneficial owner of 135,000,000 Foreign Shares. The issued share capital in HK Xinsheng Ltd comprises 170,000 Class "A" shares and 100,000 Class "B" shares.
- (h) Ms. Zhou is the registered holder and beneficial owner of 220,000 shares in HK Biochem Ltd, which is the registered holder and beneficial owner of 67,500,000 Foreign Shares. The total number of issued shares in HK Biochem Ltd is 6,750,000 shares.

INTERESTS AND SHORT POSITIONS OF THE DIRECTORS, SUPERVISORS OR CHIEF EXECUTIVES IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY SPECIFIED UNDERTAKING OF THE COMPANY OR ANY OTHER ASSOCIATED CORPORATIONS (Continued)

- (i) Mr. Lu is the registered holder and beneficial owner of 220,000 shares in HK Biochem Ltd, which is the registered holder and beneficial owner of 67,500,000 Foreign Shares. The total number of issued shares in HK Biochem Ltd is 6,750,000 shares.
- (j) Mr. Zhang is the registered holder and beneficial owner of 800 Class "B" shares in HK Xinsheng Ltd, which is the registered holder and beneficial owner of 135,000,000 Foreign Shares. The issued share capital in HK Xinsheng Ltd comprises 170,000 Class "A" shares and 100,000 Class "B" shares. Mr. Zhang is also the registered holder and beneficial owner of 120,000 shares in HK Biochem Ltd, which is the registered holder and beneficial owner of 67,500,000 Foreign Shares. The total number of issued shares in HK Biochem Ltd is 6,750,000 shares.
- (k) Prof. Jiang is the registered holder and beneficial owner of 2,000 Class "B" shares in HK Xinsheng Ltd, which is the registered holder and beneficial owner of 135,000,000 Foreign Shares. The issued share capital in HK Xinsheng Ltd comprises 170,000 Class "A" shares and 100,000 Class "B" shares.
- (I) The percentage is calculated based on the 2,500,000 Domestic Shares in issue as at 31 December 2018.
- (m) The percentage is calculated based on the 343,500,000 Foreign Shares in issue as at 31 December 2018
- (n) The percentage is calculated based on the 183,700,000 H Foreign Shares in issue as at 31 December

Save as disclosed above, as at 31 December 2018, none of the Directors, Supervisors or chief executives of the Company have interests in the shares, underlying shares and debentures of the Company or any specified undertaking of the Company or any other associated corporations (within the meaning of Part XV of the SFO) (including interests in shares and short positions) which were required to notify the Company and the Stock Exchange pursuant to: (a) Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which each of them is taken or deemed to have taken under such provisions of the SFO); or (b) Section 352 of the SFO to be entered in the register referred to in that section; or (c) Appendix 10 of the Listing Rules relating to securities transactions by Directors, and (d) the Hong Kong Companies Ordinance (Cap. 622) to be notified to the Company and the Stock Exchange.

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVE'S RIGHT TO ACQUIRE SHARES OR DEBT SECURITIES

At no time during the year was the Company, of its subsidiaries or its other associated corporation a party to any arrangement (including share option scheme) to enable the Directors, Supervisors and chief executives of the Company or any of their spouses or children under eighteen years of age to hold any interests or short position in the shares or underlying shares in or debentures of the Company or its specific undertaking or other associated corporation.

PERSONS WHO HAVE AN INTEREST OR SHORT POSITION WHICH IS DISCLOSEABLE UNDER DIVISIONS 2 AND 3 OF PART XV OF THE SFO AND SUBSTANTIAL SHAREHOLDERS

So far as known to the Directors, as at 31 December 2018, the followings, not being a Director, Supervisor or chief executive of the Company, had interests or short positions in the shares or underling shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or were substantial shareholders as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO:

Long positions in shares:

		Number of Foreign	Approximate percentage shareholding in the Foreign	Number of	Approximate Percentage shareholding in the
Name of Shareholder	Capacity	Shares	Shares (Note (e))	H Shares	H Shares (Note (f))
Hong Kong Xinsheng Pioneer Investment Company Limited	Beneficial owner	135,000,000	39.30%	-	-
Hong Kong Bio-chemical Advanced Technology Investment Company Limited	Beneficial owner	67,500,000	19.65%	-	-

PERSONS WHO HAVE AN INTEREST OR SHORT POSITION WHICH IS DISCLOSEABLE UNDER DIVISIONS 2 AND 3 OF PART XV OF THE SFO AND SUBSTANTIAL SHAREHOLDERS (Continued)

Long positions in shares: (Continued)

Name of Shareholder	Capacity	Number of Foreign Shares	Approximate percentage shareholding in the Foreign Shares	Number of H Shares	Approximate Percentage shareholding in the H Shares
			(Note (e))		(Note (f))
Jomo Limited	Beneficial owner	66,000,000	19.21%	_	_
Ms. Lam Mau	Interest of spouse, interest of controlled corporation and beneficial owner	66,000,000 (Note (a))	19.21%	2,620,000	1.43%
Kehai Venture Capital (Hong Kong) Limited	Beneficial owner	62,500,000	18.20%	_	-
上海科技創業投資股份有限公司 (Shanghai S&T Investment Company Limited*, formerly 上海科技投資股份有限公司)	Interest of controlled corporation	62,500,000 (Note (b))	18.20%	-	-
上海科技創業投資有限公司 (Shanghai Technology Entrepreneur Investment Company*, formerly 上海科技投資公司)	Interest of controlled corporation	62,500,000 (Note (c))	18.20%	-	-
上海科技創業投資(集團) 有限公司 (Shanghai S&T Venture Capital (Group) Co., Ltd.*)	Interest of controlled corporation	62,500,000 (Note (d))	18.20%	-	-

Notes:

- (a) Ms. Lam Mau and her spouse, Mr. Yu Xiao Ping (who is a Director) taken together are interested in the entire issued capital of Jomo Limited which is the registered holder and beneficial owner of 66,000,000 Foreign Shares. Ms. Lam Mau is also the beneficial owner of 2,620,000 H shares.
- (b) Shanghai S&T Investment Company Limited is the beneficial owner of 100% of the issued share capital of Kehai Venture Capital (Hong Kong) Limited, which is the registered holder and beneficial owner of 62,500,000 Foreign Shares.

PERSONS WHO HAVE AN INTEREST OR SHORT POSITION WHICH IS DISCLOSEABLE UNDER DIVISIONS 2 AND 3 OF PART XV OF THE SFO AND SUBSTANTIAL SHAREHOLDERS (Continued)

Long positions in shares: (Continued)

Notes: (Continued)

- (c) Shanghai Technology Entrepreneur Investment Company is the beneficial owner of 62.3% of the issued share capital of Shanghai S&T Investment Company Limited, which is the beneficial owner of 100% of the issued share capital of Kehai Venture Capital (Hong Kong) Limited. Kehai Venture Capital (Hong Kong) Limited is the registered holder and beneficial owner of 62,500,000 Foreign Shares.
- (d) Shanghai S&T Venture Capital (Group) Co., Ltd is the beneficial owner of 100% of the issued capital of Shanghai Technology Entrepreneur Investment Company. Shanghai Technology Entrepreneur Investment Company is the beneficial owner of 62.3% of the issued capital of Shanghai S&T Investment Company Limited, which is the beneficial owner of 100% of the issued share capital of Kehai Venture Capital (Hong Kong) Limited. Kehai Venture Capital (Hong Kong) Limited is the registered holder and beneficial owner of 62,500,000 Foreign Shares.
- (e) The percentage is calculated based on the 343,500,000 Foreign Shares in issue as at 31 December 2018.
- (f) The percentage is calculated based on the 183,700,000 H Shares in issue at 31 December 2018.

Save as disclosed above, as at 31 December 2018, the Directors are not aware of any person, not being a Director, Supervisor or chief executive of the Company, had interests or short positions in the shares or underling shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or were substantial shareholders as recorded in the register required to be kept by the Company pursuant to section 336 of the SFO.

MANAGEMENT CONTRACTS

No contract concerning the management and administration of the whole or any substantial part of the business of the Company was entered into or existed during the year.

EMOLUMENT POLICY

Employees are remunerated in accordance with the nature of the job and also on individual merit.

The emoluments of the Directors and Supervisors are determined by the Remuneration Committee, with reference to their respective contribution of time, effort and expertise on the Company's matters.

The Company has adopted a staff incentive bonus scheme, please refer to the paragraph headed "Employees" under the section headed "Management Discussion and Analysis" for details.

MAJOR CUSTOMERS AND SUPPLIERS

The percentage of purchases and sales for the year attributable to the Group's major suppliers and customers are as follows:

Purchases

	2018	2017
the largest supplierfive largest suppliers combined	22% 54%	20% 53%
Sales		
	2018	2017
the largest customerfive largest customers combined	5% 21%	8% 21%

At no time during the year have the Directors, Supervisors, their associates or any shareholders of the Company (which to the knowledge of the Directors owns more than 5% of the Company's share capital) had any interest in these major customers and suppliers.

SHARE CAPITAL STRUCTURE

As at 31 December 2018, the category of the issued shares of the Company is as follows:

	No. of Shares
H Shares (Note (a))	183,700,000
Domestic Shares (Note (b))	2,500,000
Foreign Shares (Note (c))	343,500,000
	529,700,000

Notes:

- (a) Overseas listed foreign shares in the capital of the Company, with a Rmb-denominated par value of Rmb0.10 each, which were credited as fully paid up in a currency other than Rmb and are traded in Hong Kong dollars and listed on the Main Board.
- (b) Ordinary shares in the capital of the Company, with a Rmb-denominated par value of Rmb0.10 each, which were credited as fully paid up in Rmb and issued to the promoters of the Company.
- (c) Ordinary shares in the capital of the Company, with a Rmb-denominated par value of Rmb0.10 each, which were credited as fully paid up in a currency other than Rmb and issued to the promoters of the Company.

SHARE CAPITAL STRUCTURE (Continued)

The H Shares were listed on GEM on 28 June 2002 and the listing of which was transferred from GEM to the Main Board on 28 June 2013.

Although the 到境外上市公司章程必備條款 (the Mandatory Provisions of the Articles of Association of Companies Seeking a Listing Outside the PRC) promulgated on 27 August 1994 by the Securities Commission of the State Council of the PRC and the State Commission for Restructuring the Economic System of the PRC provide for the definitions of "domestic shares", "foreign shares" and "overseas listed foreign shares" (which definitions have been adopted in the Articles of Association of the Company), the rights attached to Foreign Shares (which are subject to certain restrictions on transfer and may become H Shares upon obtaining the requisite approvals from, among other bodies, the China Securities Regulatory Commission and the Stock Exchange) have not yet been expressly dealt with under the existing PRC laws or regulations. However, the creation by the Company and the subsistence of the Foreign Shares do not contravene any PRC laws or regulations.

At present, there are no applicable PRC laws and regulations governing the rights attached to the Foreign Shares. Jingtian & Gongcheng, the legal adviser to the Company as to PRC Law, have advised the Company that until new laws or regulations are introduced in this respect, holders of Foreign Shares shall have the same rights and obligations as those of the holders of Domestic Shares (in particular, in respect of the right to attend and vote in the general meetings and class meetings and to receive notice of such meetings in the same manner applicable to holders of Domestic Shares), except that holders of Foreign Shares shall enjoy the following rights:

- (a) to receive dividends declared by the Company in foreign currencies;
- (b) in the event of the winding up of the Company, to participate in the distribution of surplus assets (if any) of the Company in foreign currencies and transfer such assets out of PRC, subject however to the applicable foreign exchange control regulations;
- (c) disputes between holders of Domestic Shares and Foreign Shares may upon agreement between them may be resolved by way of arbitration and in case no such agreement is reached, any of the disputing parties could submit the dispute to the courts with competent jurisdiction for determination. These methods of dispute resolution apply equally to disputes between holders of Foreign Shares and overseas listed foreign shares; and
- (d) upon all necessary approvals from the relevant regulatory authorities in the PRC and the Stock Exchange being obtained, the Foreign Shares may be converted into overseas listed foreign shares and shall thereafter carry the same rights and obligations attaching to overseas listed foreign shares.

PUBLIC FLOAT

As at the date of this report, the Company has maintained the prescribed public float under the Listing Rules, based on the information that is publicly available to the Company and within the knowledge of the Directors.

RETIREMENT SCHEMES

Details of the retirement schemes are set out in notes 2.21(a) and 12 to the consolidated financial statements.

BUSINESS REVIEW

(a) Business performance and future development

Discussion on the business performance and future development of the Group is set out in the session headed "Chairman's Statement" in this Annual Report.

Analysis of the key performance indicators of the Group is set out in the session headed "Management Discussion and Analysis" in this Annual Report.

These discussions form part of the "Report of the Directors".

(b) Environmental policies and performance

Discussions on the environment policies and performance of the Group are set out in the "Environmental and Social Report" in this Annual Report. These discussions form part of the "Report of the Directors".

(c) Laws and regulations that have a significant impact on the Company

The Group is mainly engaged in the production of organic acids products, which are used as food additives and pharmaceutical intermediates, etc. Accordingly, the Group is required to comply with relevant laws and regulations on environmental protection. It is also required to comply with the Law of Work Safety, Food Safety Law, Labour Contract Law and Company Law, etc. in the PRC. The H shares of the Company are listed on the Main Board, therefore the Company also needs to comply with the Listing Rules and the disclosure requirements the Hong Kong Companies Ordinance.

The Group did not aware of any non-compliance with applicable laws and regulations that have a significant impact on the Group for the year ended 31 December 2018.

BUSINESS REVIEW (Continued)

(d) Key relationships

Discussions on the relationships with employees, customers and suppliers of the Group are set out in the "Environmental and Social Report" in this Annual Report. These discussions form part of the "Report of the Directors".

(e) Principal risks and uncertainties

Certain significant risks have been identified through the process of risk identification and assessment. A summary on such significant risks of the Group together with the relevant internal control measures or mitigation in place is listed below:

1. Research and development

The Group has two research centres. The Group will invest in research and development to improve existing production technologies and develop new production technologies each year. The Group's future prospects will be dependent upon the successful development and commercialisation of products currently under development. Successful development is, however, uncertain. There is also no assurance that a product can receive market acceptance and is competitive in the market. The Group will take into account the prospect of new markets, sales prices and costs of new products before making decision to invest in research and development to control the relevant risks.

2. Tax relief

The Group's net profit mainly comes from the company's production base in Changzhou. The Company, qualified as a New and High Technology Enterprise, is entitled to a preferential CIT rate of 15%. If the Company is fail to renew such qualification, there will be a material impact on the Group's profit. The Company continues to actively co-ordinated different departments on monitoring the compliance of requirements on New and High Technology Enterprise qualification and strives to continue to enjoy the relevant tax relief.

BUSINESS REVIEW (Continued)

e) Principal risks and uncertainties (Continued)

3. Volatility of prices for raw materials

The Group's main raw material is butane, mainly purchased from Chinese suppliers. The price for butane are affected by various factors and the Group does not and will not control over those factors. Those factors include the prices of crude oil, global and regional supply and demand for butane, domestic and foreign government regulations, weather conditions and global economic conditions. Any increase in the price of butane which cannot be passed on to the Group's customers may adversely affect the Group's business and results of operations.

4. Competition

Approximately 49% of the Group's products are exported overseas, while approximate 51% of the sales are in the domestic (including import and export companies) market for the year ended 31 December 2018. Whether in foreign or domestic market, food additives and pharmaceutical intermediates industry are intensively competitive. Any increase in the level of competition could result in price reduction and erode the Group's market share and gross profit margin. The Group continuously monitors and analyses the competitive situation and market information and makes early estimate to adverse movements and takes corresponding measures. The Group has also taken measures to strengthen the brand, to promote business growth and consolidate the brand's market position. In addition, the Group continues to make improvement on production technologies to reduce production costs and improve product quality so that its products will be more competitive.

PERMITTED INDEMNITY PROVISIONS

At no time during the financial year and up to the date of this Directors' Report, there was or is, any permitted indemnity provision being in force for the benefit of any of the directors of the Company (whether made by the Company or otherwise) or an associated company (if made by the Company).

AUDITOR

The consolidated financial statements have been audited by PricewaterhouseCoopers who retire and, being eligible, offer themselves for re-appointment.

By order of the Board

Rui Xin Sheng Chairman

The PRC, 12 March 2019

REPORT OF THE SUPERVISORY COMMITTEE

To the Shareholders,

During the year ended 31 December 2018, the supervisory committee of Changmao Biochemical Engineering Company Limited (the "Supervisory Committee"), exercised conscientiously its authority, safeguarded the interests of the shareholders and the Company, followed the principle of trustworthiness, honestly carried out the duties of supervisors and worked cautiously and diligently, in accordance with the Company Law of the PRC, requirements of the relevant laws and regulations of Hong Kong and the Articles of Association of the Company for their accountability to the shareholders.

During the year, the major work performed by the Supervisory Committee included the attendance of the Board meetings; reviewing the report of the Directors and the reserve appropriation proposal prepared to be submitted by the Board for the shareholders' approval at the forthcoming annual general meeting; strictly and effectively monitored that whether the policies and decisions made by the management of the Company had conformed with the state laws and regulations of the PRC and the Articles of Association of the Company or safeguarded the interest of the shareholders. The Supervisory Committee has also reviewed the performance of the Directors, general manager and senior management in the daily operation by various means; seriously examined the Company's financial affairs and its connected transactions.

After the examination, the Supervisory Committee concluded that:

- 1. the report of the Directors and the reserve appropriation proposal prepared to be submitted by the Board for the shareholders' approval at the forthcoming annual general meeting are in accordance with the relevant laws and regulations and the Articles of Association of the Company;
- 2. the Directors, general manager and other senior management of the Company have strictly followed the principles of trustworthiness, worked diligently and responsibly, and discharged their duties for the best interest of the Company. The Supervisory Committee has not discovered that any Directors, general manager and other senior management of the Company have abused their powers, damaged the interest of the Company or the benefits of the shareholders and employees nor contravened any laws and regulations or the Articles of Association of the Company;

REPORT OF THE SUPERVISORY COMMITTEE

3. the consolidated financial statements of the Group for the year ended 31 December 2018, which have been audited by PricewaterhouseCoopers, reflected truly and fairly the operating results and financial position of the Company and its subsidiaries. The connected transactions were in compliance with the Listing Rules and were fair and reasonable and had not infringed upon the interest of the Company and the shareholders.

The Supervisory Committee takes this opportunity to thank the shareholders, Directors and all the employees of the Company for their supports in the past year!

By order of the Supervisory Committee

Zhou Rui Juan

Chairman of the Supervisory Committee

The PRC, 12 March 2019



羅兵咸永道

To the Shareholders of Changmao Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)

OPINION

What we have audited

The consolidated financial statements of Changmao Biomedical Engineering Company Limited (the "Company") and its subsidiaries (the "Group") set out on pages 66 to 133, which comprise:

- the consolidated balance sheet as at 31 December 2018;
- the consolidated statement of comprehensive income for the year then ended;
- the consolidated statement of changes in equity for the year then ended;
- the consolidated cash flow statement for the year then ended; and
- the notes to the consolidated financial statements, which include a summary of significant accounting policies.

Our opinion

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2018, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

BASIS FOR OPINION

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSAs") issued by the HKICPA. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Group in accordance with the HKICPA's Code of Ethics for Professional Accountants ("the Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code.

KEY AUDIT MATTERS

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matters identified in our audit are summarised as follows:

- Impairment of non-financial assets of production plants in Lianyungang
- Net realisable value of inventories

Key Audit Matter

How our audit addressed the Key Audit Matter

Impairment of non-financial assets of production plants in Lianyungang

Refer to notes 4(a), 15, 16 and 17 to the consolidated financial statements

As at 31 December 2018, the Group has certain non-financial assets, including property, plant and equipment, land use rights and construction in progress related to the production plants in Lianyungang ("Lianyungang Changmao") amounting to approximately RMB153 million. The production plants in Lianyungang commenced operations since early 2016 and have been operating at loss since its commencement of operations while planned production level is still yet to be attained. The plant is also temporarily suspended as detailed in Note 4(a).

Management considered the operating losses and temporary suspension of the production of Lianyungang Changmao as impairment indicators on the non-financial assets of these plants and has performed an impairment assessment on these assets as at 31 December 2018. Based on the results of the assessment, it is concluded that no provision for impairment of the above non-financial assets of Lianyungang Changmao is required.

We focused on this area because the carrying amounts of the above non-financial assets of Lianyungang Changmao are significant to the consolidated financial statements, the existence of impairment indicators and the determination of recoverable amount of these assets, using value-in-use calculations, require significant judgements and estimates by the management about the future results of the related business and the discount rate applied to the cash flow forecast.

Our audit procedures in relation to management's assessment on impairment of non-financial assets of Lianyungang Changmao included:

- Obtained, understood and evaluated management's impairment assessment process;
- Tested the mathematical accuracy of the value-in-use calculation of the cash flow forecast and assessed the appropriateness of the methodology used. We independently evaluated the appropriateness of the key assumptions, including revenue growth rate and gross profit margin, based on other available market data in the food additives industry in the People's Republic of China taking into account the historical performance of the Group. We obtained, understood and evaluated the timing of Lianyungang Changmao's restoration of production estimated by management based on Lianyungang Changmao's correspondence with the relevant authority, including its detailed compliance assessments, and publicly available information, and did not identify any matter that is contradictory to the assumptions. We also evaluated the appropriateness of the discount rate used by considering Lianyungang Changmao's weighted average cost of capital and comparable companies; and
- Assessed the appropriateness of management's sensitivity analysis over the timing of restoration of production and the above key assumptions of the cash flow forecast in order to assess the potential impact of a range of possible outcomes and evaluated the likelihood of such a movement based on the historical experience of the Group and market trend in the industry.

Based on the procedures described above, we found the methodology used, and key assumptions and estimates applied by management in the impairment assessment of non-financial assets of Lianyungang Changmao are supportable by available evidence.

Key Audit Matter

How our audit addressed the Key Audit Matter

Net realisable value of inventories

Refer to notes 4(b) and 20 to the consolidated financial statements

As at 31 December 2018, the Group held inventories of approximately RMB108 million, net of impairment provision of approximately RMB1.3 million. Inventories are carried at the lower of cost and net realisable value. Management determines the net realisable value of inventories by considering the ageing profile, estimated selling price and physical condition of the inventory on a product-by-product basis.

Management performed periodic inventory counts to identify defective or obsolete inventories.

Management determined the provision for slow-moving inventories based on inventory ageing and applied judgement to make specific provision for long aged inventories.

Management also applied judgement in determining the estimated selling price less cost to sell based on historical experience of selling products of similar nature and expectation of future sales based on current market conditions and available information.

We focused on the net realisable value of inventories due to the size of the inventories balance and the judgment involved by management in determining the net realisable value of the inventories.

Our audit procedures in relation to management's assessment on the net realisable value of inventories included:

- Tested key inventory controls across the Group;
- Observed inventory counts to identify defective or obsolete inventories;
- Tested, on a sample basis, the accuracy of the ageing profile of individual inventory items by checking to the underlying procurement correspondence and purchase invoices;
 - Tested, on a sample basis, the estimated selling price of significant inventory items to the actual selling price subsequent to the year end or latest sales data and compared the estimated selling price of selected inventory items against its costs. We discussed with management as to its assessment on the net realisable value of the inventory items with no subsequent sales after the year end, corroborating explanations with sales orders, current market price of similar products, historical margins and marketability of relevant inventories, as appropriate; and
- Tested, on a sample basis, the subsequent utilisation of raw materials, and subsequent sales by products to identify slow moving inventories. We discussed with management to understand its provision assessment for those raw materials or products with no subsequent utilisation or sales by corroborating explanations with the inventory ageing, sales orders and marketability of the relevant inventories, as appropriate.

Based on the procedures described above, we found the assumptions made by management in relation to the assessment on net realisable value of inventories are supportable by available evidence.

OTHER INFORMATION

The directors of the Company are responsible for the other information. The other information comprises all of the information included in the annual report other than the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

RESPONSIBILITIES OF DIRECTORS AND AUDIT COMMITTEE FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors of the Company are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with HKFRSs issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

The audit committee is responsible for overseeing the Group's financial reporting process.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. We report our opinion solely to you, as a body, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with HKSAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with the audit committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the audit committee with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the audit committee, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in this independent auditor's report is Ho Chiu Yin, Ivan.

PricewaterhouseCoopers

Certified Public Accountants

Hong Kong, 12 March 2019

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 December 2018

	Note	2018 Rmb′000	201 <i>7</i> Rmb′000
Revenue	5	639,120	630,841
Cost of sales	7	(509,394)	(555,846)
Cupas puolit		120 726	74.005
Gross profit Other income	6	129,726 4,018	74,995 12,784
Other gains/(losses), net	6	1,737	(5,889)
Selling expenses	7	(15,169)	(18,464)
Administrative expenses	7	(63,554)	(62,389)
(Loss allowance)/reversal of loss allowance			
on financial assets	7	(1,304)	178
Operating profit		55,454	1,215
Finance income		296	261
Finance costs		(1,149)	(232)
Finance (costs)/income, net	8	(853)	29
D. Cal. C.		F.4.604	1.044
Profit before income tax	0	54,601	1,244
Income tax (expense)/credit	9	(4,692)	1,456
Profit for the year		49,909	2,700
Other comprehensive income			
Item that may be reclassified to profit or loss			
currency translation difference		1	(2)
Total comprehensive income for the year		49,910	2,698
Due fix for the construction to be a construction			
Profit for the year attributable to:		E0 E0E	2 202
Equity holders of the Company		50,525	3,382
Non-controlling interests		(616)	(682)
		49,909	2,700
Total comprehensive income for the year attributable to:			
Equity holders of the Company		50,526	3,380
Non-controlling interests		(616)	(682)
		49,910	2,698
		73,310	2,030
Earnings per share for profit attributable to			
equity holders of the Company	10	D 10005	D 10005
– basic and diluted	10	Rmb0.095	Rmb0.006

CONSOLIDATED BALANCE SHEET

AS AT 31 December 2018

		2018	2017
	Note	Rmb′000	Rmb′000
ASSETS			
Non-current assets			
Patents	14	660	744
Property, plant and equipment	15	292,537	299,237
Land use rights	16	25,943	26,642
Construction in progress	17	87,531	79,826
Deferred income tax assets	29	13,949	8,788
Bank deposits	23		1,700
		420,620	416,937
Current assets			
Inventories	20	108,024	115,335
Trade and bills receivables	21	98,672	87,148
Other receivables, deposits and prepayments	22	16,830	23,466
Income tax recoverable		_	1,223
Pledged bank balances	23	2,774	15,671
Cash and bank balances	23	85,098	72,602
		311,398	315,445
Total assets		732,018	732,382
		, 52,616	, 52,552
EQUITY			
Capital and reserves attributable to the Company's equity holders			
Share capital	24	52,970	52,970
Reserves	25	576,903	526,377
		629,873	579,347
Non-controlling interests		994	1,610
Total equity		630,867	580,957

CONSOLIDATED BALANCE SHEET (Continued)

AS AT 31 December 2018

	Note	2018 Rmb′000	2017 Rmb′000
LIABILITIES			
Non-current liabilities			
Deferred income	27	1,945	2,430
Deferred income tax liabilities	29	494	484
		2,439	2,914
Current liabilities			
Trade and bills payables	26	19,781	73,505
Contract liabilities, other payables and accruals	27	37,055	20,988
Income tax payable		2,565	11
Bank borrowings	28	39,311	54,007
		98,712	148,511
Total liabilities		101,151	151,425
Total equity and liabilities		732,018	732,382

The financial statements on pages 66 to 133 were approved by the Board of Directors on 12 March 2019 and were signed on its behalf

Rui Xin Sheng
Director

Pan Chun Director

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 December 2018

Attributable to equity holders of the Company

						_	
	Note	Share capital Rmb′000	Other reserves Rmb′000	Retained earnings Rmb'000	Sub-total Rmb'000	Non- controlling interests Rmb'000	Total Rmb′000
Balance at 1 January 2017		52,970	181,813	351,778	586,561	2,292	588,853
Transfer to statutory reserve	25	_	1,170	(1,170)	_	_	_
Profit for the year		_	_	3,382	3,382	(682)	2,700
Other comprehensive income -currency translation difference – Group		_	(2)	_	(2)	_	(2)
Final dividend for the year							
ended 31 December 2016	11	_	_	(10,594)	(10,594)	_	(10,594)
Balance at 31 December 2017		52,970	182,981	343,396	579,347	1,610	580,957
Balance at 1 January 2018		52,970	182,981	343,396	579,347	1,610	580,957
Transfer to statutory reserve	25	_	7,272	(7,272)	_	_	_
Profit for the year		_	_	50,525	50,525	(616)	49,909
Other comprehensive income -currency translation							
difference – Group		_	1	_	1	_	1
Balance at 31 December 2018		52,970	190,254	386,649	629,873	994	630,867

CONSOLIDATED CASH FLOW STATEMENT

FOR THE YEAR ENDED 31 December 2018

	Note	2018 Rmb′000	201 <i>7</i> Rmb′000
	Note	Killb 000	KIIID 000
Cash flows from operating activities			
Cash generated from operations	30(a)	51,819	67,904
Interest paid		(1,278)	(1,203)
Income tax paid		(6,063)	(920)
Net cash generated from operating activities		44,478	65,781
Cash flows from investing activities			
Purchase of property, plant and equipment		(8)	(31)
Proceeds from disposal of property, plant and equipmer	276	368	
Additions of construction in progress	(32,894)	(49,861)	
Government grants received	1,088	2,167	
Decrease/(increase) in pledged bank balances	12,897	(10,605)	
Decrease/(increase) in long-term and short-term		,	, , ,
bank deposits with maturities of over 3 months		1,850	(2,650)
Interest received		296	261
Net cash used in investing activities		(16,495)	(60,351)
Cash flows from financing activities			
Proceeds from new bank borrowings	30(b)	73,004	105,945
Repayment of bank borrowings	30(b)	(88,342)	(79,843)
Dividends paid	30(b)		(10,594)
Net cash (used in)/generated from financing activities		(15,338)	15,508
Net increase in cash and cash equivalents		12,645	20,938
Effect of foreign exchange rate changes		1	(2)
Cash and cash equivalents at 1 January		68,752	47,816
Cash and cash equivalents at 31 December	23	81,398	68,752

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1 GENERAL INFORMATION

Changmao Biochemical Engineering Company Limited (the "Company") is a joint stock limited company incorporated in the People's Republic of China (the "PRC"). The Company formerly listed its H shares on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited ("SEHK") on 28 June 2002 which was then transferred to the Main Board of the SEHK on 28 June 2013. The principal activities of the Company and its subsidiaries (together, the "Group") are the production and sales of organic acids products.

The address of the Company's registered office is No.1228 Chang Jiang Bei Road, New North Zone, Changzhou City, Jiangsu Province, 213034, the PRC.

These consolidated financial statements are presented in Renminbi, unless otherwise stated. These consolidated financial statements have been approved for issue by the Board of Directors on 12 March 2019.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This note provides a list of the significant accounting policies adopted in the preparation of these consolidated financial statements. These policies have been consistently applied to all the years presented, unless otherwise stated. The consolidated financial statements are for the group consisting of Changmao Biochemical Engineering Company Limited and its subsidiaries.

2.1 Basis of preparation

The consolidated financial statements of Changmao Biochemical Engineering Company Limited have been prepared in accordance with all applicable Hong Kong Financial Reporting Standards ("HKFRS") and disclosure requirements of the Hong Kong Companies Ordinance Cap. 622. The financial statements have been prepared on a historical cost basis.

The preparation of the consolidated financial statements in conformity with HKFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements is disclosed in Note 4.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.1 Basis of preparation (Continued)

(a) New and amended standards, improvements and interpretation adopted by the Group

The Group has applied the following new and amended standards, improvements and interpretation for the first time for their annual reporting period commencing 1 January 2018:

HKFRS 9 Financial Instruments

HKFRS 15 Revenue from Contracts with Customers
HKFRS 2 (Amendments) Classification and Measurement of Share-

based Payment Transactions

HKFRS 4 (Amendments) Applying HKFRS 9 Financial Instruments with

HKFRS 4 Insurance Contracts

Annual Improvements Project Annual Improvements 2014-2016 Cycle

HKFRS 15 (Amendments) Clarifications to HKFRS 15
HKAS 40 (Amendments) Transfers of Investment Property

HK(IFRIC)-Int 22 Foreign Currency Transactions and Advance

Consideration

To conform with current year presentation, impairment losses on financial assets reclassified from administrative expenses in 2017 as a result of consequential changes made to HKAS 1 Presentation of Financial Statements. Impairment losses on financial assets that were previously classified as administrative expenses are now presented separately in the consolidated statement of comprehensive income.

Saved as disclosed in Note 2.1(c), the adoption of these new and amended standards, improvements and interpretation did not have any impact on the amounts recognised in prior periods and will also not affect the current or future periods.

Effective for annual periods beginning

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.1 Basis of preparation (Continued)

(b) New and amended standards, interpretation and revised framework not yet adopted

A number of new and amended standards and interpretations have been published that are not mandatory for the year ended 31 December 2018 and have not been early adopted by the Group.

		on or after
Annual Improvements Project (Amendments)	Annual Improvements 2015-2017 Cycle	1 January 2019
HKAS 1 (Revised)	Presentation of Financial Statement	1 January 2020
HKAS 8 (Amendments)	Accounting Policies, Changes in Accounting Estimates and Errors	1 January 2020
HKAS 19 (Amendments)	Plan Amendment, Curtailment or Settlement	1 January 2019
HKAS 28 (Amendments)	Long-term Interests in Associates and Joint Ventures	1 January 2019
HKFRS 3 (Amendments)	Business Combinations	1 January 2020
HKFRS 9 (Amendments)	Prepayment Features with Negative Compensation	1 January 2019
HKFRS 17	Insurance Contracts	1 January 2021
Conceptual Framework for Financial Reporting 2018	Revised Conceptual Framework for Financial Reporting	1 January 2020
HK(IFRIC) 23	Uncertainty Over Income Tax Treatments	1 January 2019
HKFRS 16	Leases	1 January 2019
HKFRS 10 and HKAS 28	Sale or Contribution of	A date to be
(Amendments)	Assets Between an Investor and Its Associate or Joint Venture	determined

The Group will apply the above new and amended standards and interpretation and revised framework when they become effective. The Group has commenced the assessment of the expected impact of HKFRS 16 as set out below. The directors of the Company is in the process of assessing the financial impact of the other new and amended standards, interpretation and revised framework, but is not yet in a position to state whether they would have significant impacts on its results of operations and financial position.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.1 Basis of preparation (Continued)

(b) New and amended standards, interpretation and revised framework not yet adopted (Continued)

HKFRS 16 Leases

Nature of change

HKFRS 16 was issued in January 2016. It will result in almost all leases being recognised on the consolidated balance sheet, as the distinction between operating and finance leases is removed. Under the new standard, an asset (the right to use the leased item) and a financial liability to pay rentals are recognised. The only exceptions are short-term and low-value leases. The accounting for lessors will not significantly change.

Impact

The standard will affect primarily the accounting for the Group's operating leases. As at the reporting date, the Group has non-cancellable operating lease commitments of Rmb260,000, see note 31.

For the lease commitments the Group expects to recognise right-of-use assets on 1 January 2019 and lease liabilities (after adjustments for prepayments and accrued lease payments recognised as at 31 December 2018). Net current assets may be lower due to the presentation of a portion of the liability as a current liability.

The commitments may be covered by the exception for short-term and low value leases. Accordingly, the Group does not expect the new standard to have a significant impact on the Group's consolidated financial statements.

Mandatory application date/Date of adoption by the Group

Mandatory for financial years commencing on or after 1 January 2019. The Group intends to apply the simplified transition approach and last year comparatives do not have to restate as the lease commitments are short term.

There are no other new and amended standards and interpretations that are not yet effective and that would be expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.1 Basis of preparation (Continued)

(c) Changes in accounting policies

The Group elects to adopt HKFRS 9 and HKFRS 15 without restating comparatives. The reclassification and the adjustments arising from the adoption of HKFRS 9 and HKFRS 15 are therefore not reflected in the consolidated balance sheet as at 31 December 2017, but are recognised in the opening of the consolidated balance sheet on 1 January 2018.

The following tables show the adjustments recognised for each individual line item. Line items that were not affected by the changes have not been included. As a result, sub-totals and totals disclosed cannot be recalculated from the numbers provided. The adjustments are explained in more details by standard below.

	31 December		
	2017		1 January
Consolidated balance sheet	As originally		2018
(extract)	presented	HKFRS 15	Restated
	Rmb′000	Rmb′000	Rmb′000
Current liabilities			
Contract liabilities, other			
payables and accruals			
 Receipt in advance 	2,279	(2,279)	_
 Contract liabilities 	_	2,279	2,279
– Others	18,709		18,709
	20,988	_	20,988

2 **SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES** (Continued)

2.1 Basis of preparation (Continued)

- c) Changes in accounting policies (Continued)
 - HKFRS 9 Financial Instruments

 HKFRS 9 replaces the provisions of HKAS 39 that relate to the recognition, classification and measurement of financial assets and financial liabilities, derecognition of financial instruments, impairment of financial assets and hedge accounting.

The adoption of HKFRS 9 Financial Instruments from 1 January 2018 resulted in changes in accounting policies and adjustments to the amounts recognised in the consolidated financial statements. The new accounting policies are set out in notes 2.10 and 2.14 below. In accordance with the transitional provisions in HKFRS 9(7.2.15) and (7.2.26), comparative figures have not been restated.

(1) Classification and measurement of financial instruments on adoption of HKFRS 9

The financial assets currently held by the Group include financial instruments previously classified as loans and receivables which continue to be measured at amortised cost under HKFRS 9. Accordingly, there is no impact on the classification and measurement of its financial assets. There will be no impact on the Group's accounting for financial liabilities, as the HKFRS 9 only affect the accounting for financial liabilities that are designated at fair value through profit or loss and the Group does not have any such liabilities. The derecognition rules have been transferred from HKAS 39 and have not been changed.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.1 Basis of preparation (Continued)

- (c) Changes in accounting policies (continued)
 - (i) HKFRS 9 Financial Instruments (continued)
 - (2) Impairment of financial assets
 The Group has two types of financial assets that are subject to
 HKFRS 9's expected credit loss model:
 - trade and bills receivables
 - other receivables and deposits

The Group was required to revise its impairment methodology under HKFRS 9 for each of these classes of assets. The impact of the change in impairment methodology on the Group's retained earnings and equity was immaterial.

While pledged bank balances and cash and cash equivalents are also subject to the impairment requirements of HKFRS 9, the identified loss allowance was also immaterial.

Trade receivables

The Group applies the HKFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. The resulted increase of loss allowance for trade receivables on 1 January 2018 was immaterial. Note 3.1(b) provides for details about the calculation of the allowance.

Other receivables and deposits

Loss allowance on other receivables and deposits from third parties are measured as either 12-months expected credit losses or lifetime expected credit losses, depending on whether there has been a significant increase in credit risk since initial recognition. If a significant increase in credit risk of a receivable has occurred since initial recognition, then loss allowance is measured as lifetime expected credit losses. The resulted increase of loss allowance for other receivables and deposits on 1 January 2018 was immaterial. The loss allowance for other receivables and deposits have increased by Rmb244,000 during the year ended 31 December 2018.

2 **SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES** (Continued)

2.1 Basis of preparation (Continued)

- c) Changes in accounting policies (continued)
 - (ii) HKFRS 15 Revenue from contracts with customers

The Group has adopted HKFRS 15 Revenue from Contracts with Customers from 1 January 2018, which resulted in changes in accounting policies and adjustments to the amounts recognised in the consolidated financial statements. In accordance with the transition provisions in HKFRS 15, comparative figures have not been restated. The adoption of HKFRS 15 did not result in significant changes to the Group recognition policies.

The Group has voluntarily changed the presentation of certain amounts in the consolidated balance sheet to reflect the terminology of HKFRS 15. As such, receipt in advance from customers which was previously included in trade and other payables, amounting to Rmb2,279,000 as at 1 January 2018, are now recognised as contract liabilities (as included in trade and other payables) to reflect the terminology of HKFRS 15.

2.2 Subsidiaries

(a) Consolidation

The consolidated financial statements include the financial statements of the Company and all of its subsidiaries made up to 31 December 2018.

A subsidiary is an entity (including a structured entity) over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

The Group applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair values of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Group. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.2 Subsidiaries (Continued)

(a) Consolidation (Continued)

The Group recognises any non-controlling interest in the acquiree on an acquisition-by-acquisition basis. Non-controlling interests in the acquiree that are present ownership interests and entitle their holders to a proportionate share of the entity's net assets in the event of liquidation are measured at either fair value or the present ownership interest's proportionate share in the recognised amounts of the acquiree's identifiable net assets. All other components of non-controlling interests are measured at their acquisition date fair value, unless another measurement basis is required by HKFRS.

Acquisition-related costs are expensed as incurred.

If the business combination is achieved in stages, the acquisition date carrying value of the acquirer's previously held equity interest in the acquiree is remeasured to fair value at the acquisition date; any gains or losses arising from such re-measurement are recognised in profit or loss.

Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity's incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions. Contingent consideration is classified either as equity or a financial liability. Amounts classified as a financial liability are subsequently remeasured to fair value with changes in fair value recognised in profit or loss.

The excess of the consideration transferred, the amount of any non-controlling interest in the acquiree and the acquisition-date fair value of any previous equity interest in the acquiree over the fair value of the identifiable net assets acquired is recorded as goodwill. If the total of consideration transferred, non-controlling interest recognised and previously held interest measured is less than the fair value of the net assets of the subsidiary acquired in the case of a bargain purchase, the difference is recognised directly in profit or loss.

Intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated. Unrealised losses are also eliminated. When necessary, amounts reported by subsidiaries have been adjusted to conform with the Group's accounting policies.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.2 Subsidiaries (Continued)

(a) Consolidation (Continued)

Transactions with non-controlling interests that do not result in loss of control are accounted for as equity transactions – that is, as transactions with the owners of the subsidiary in their capacity as owners. The difference between fair value of any consideration paid and the relevant share acquired of the carrying amount of net assets of the subsidiary is recorded in equity. Gains or losses on disposals to non-controlling interests are also recorded in equity.

When the Group ceases to have control, any retained interest in the entity is re-measured to its fair value at the date when control is lost, with the change in carrying amount recognised in profit or loss. The fair value is the initial carrying amount for the purposes of subsequently accounting for the retained interest as an associate, joint venture or financial asset. In addition, any amounts previously recognised in other comprehensive income in respect of that entity are accounted for as if the Group had directly disposed of the related assets or liabilities. This may mean that amounts previously recognised in other comprehensive income are reclassified to profit or loss.

(b) Separate financial statements

Investments in subsidiaries are accounted for at cost less impairment. Costs include direct attributable costs of investment. The results of subsidiaries are accounted for by the Company on the basis of dividend received and receivable.

Impairment testing of investments in subsidiaries is required upon receiving dividends from these investments if the dividend exceeds the total comprehensive income of the subsidiary in the period the dividend is declared or if the carrying amount of the investment in the separate financial statements exceeds the carrying amount in the consolidated financial statements of the investee's net assets including goodwill.

2.3 Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the executives directors that makes strategic decisions.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.4 Foreign currency translation

(a) Functional and presentation currency

Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). The consolidated financial statements are presented in Renminbi ("Rmb"), which is the Company's functional and the Group's presentation currency.

(b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss, except when deferred in other comprehensive income as qualifying cash flow hedges or qualifying net investment hedges.

All other foreign exchange gains and losses are presented in the consolidated statement of comprehensive income within "other gains/(losses), net".

(c) Group companies

The results and financial position of all the Group entities (none of which has the currency of a hyper-inflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

- (i) assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet;
- (ii) income and expenses for each income statement are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the rate on the dates of the transactions); and
- (iii) all resulting currency translation differences are recognised in other comprehensive income.

Goodwill and fair value adjustments arising on the acquisition of a foreign entity are treated as assets and liabilities of the foreign entity and translated at the closing rate. Currency translation differences arising are recognised in other comprehensive income.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.4 Foreign currency translation (Continued)

(d) Disposal of foreign operation and partial disposal

On the disposal of a foreign operation (that is, a disposal of the Group's entire interest in a foreign operation, or a disposal involving loss of control over a subsidiary that includes a foreign operation, or a disposal involving loss of joint control over a joint venture that includes a foreign operation, or a disposal involving loss of significant influence over an associate that includes a foreign operation), all of the currency translation differences accumulated in equity in respect of that operation attributable to the equity holders of the Company are reclassified to profit or loss.

In the case of a partial disposal that does not result in the Group losing control over a subsidiary that includes a foreign operation, the proportionate share of accumulated currency translation differences are re-attributed to non-controlling interests and are not recognised in profit or loss. For all other partial disposals (that is, reductions in the Group's ownership interest in associates or joint ventures that do not result in the Group losing significant influence or joint control) the proportionate share of the accumulated exchange difference is reclassified to profit or loss.

2.5 Patents

Patents are stated at cost less accumulated amortisation and accumulated impairment losses, if any. Patents are amortised using the straight-line method over their estimated useful lives as follows:

Acid patent 15 years Nutraceutical patent 19 years

Where an indication of impairment exists, the carrying amounts of the patents are assessed and written down immediately to their recoverable amounts.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.6 Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognised. All other repairs and maintenance are charged to the profit or loss during the financial period in which they are incurred.

Depreciation on property, plant and equipment is calculated using the straight-line method to allocate their costs less accumulated impairment losses to their estimated residual values over their estimated useful lives, as follows:

Buildings 20-50 years
Plant and machinery 10 years
Equipment and motor vehicles 5 years

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains or losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised within "other gains/(losses), net" in the consolidated statement of comprehensive income.

2.7 Land use rights

Land use rights are stated at cost less accumulated amortisation and accumulated impairment losses, if any. Land use rights are amortised using the straight-line method over their estimated useful lives of 50 years.

Where an indication of impairment exists, the carrying amounts of the land use rights are assessed and written down immediately to their recoverable amounts.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.8 Construction in progress

Construction in progress is stated at cost, which comprises construction costs, purchase costs, interest and other direct costs incurred in connection with the construction of buildings, plant and machinery for own use, less accumulated impairment losses, if any.

No depreciation is provided for in respect of construction in progress until the construction and installation is completed and ready for their intended use, upon which they will be transferred to appropriate categories of property, plant and equipment.

2.9 Impairment of non-financial assets

Assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment. Assets that are subject to amortisation/depreciation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value-in-use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at each reporting date.

Impairment testing of the investments in subsidiaries is required upon receiving a dividend from these investments if the dividend exceeds the total comprehensive income of the subsidiary in the period the dividend is declared or if the carrying amount of the investment in the separate financial statements exceeds the carrying amount in the consolidated financial statements of the investee's net assets including goodwill.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.10 Financial assets

(a) Classification

From 1 January 2018, the Group classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value (either through other comprehensive income ("OCI") or through profit or loss), and
- those to be measured at amortised cost.

The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows.

For assets measured at fair value, gains and losses will either be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income ("FVOCI").

(b) Recognition and derecognition

Regular way purchases and sales of financial assets are recognised on trade-date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership.

(c) Measurement

At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss ("FVPL"), transaction costs that are directly attributable to the acquisition of the financial asset.

Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on derecognition is recognised directly in profit or loss and presented in "other gains/(losses)" together with foreign exchange gains and losses. Losses allowance are presented as separate line item in the consolidated statement of comprehensive income.

2 **SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES** (Continued)

2.10 Financial assets (Continued)

(d) Impairment

From 1 January 2018, the Group assesses on a forward looking basis the expected credit losses associated with its financial assets carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk.

For trade receivables, the Group applies the simplified approach permitted by HKFRS 9, which requires expected lifetime losses to be recognised from initial recognition of the receivables, see note 3.1(b) for further details.

(e) Accounting policies applied until 31 December 2017

The Group has applied HKFRS 9 retrospectively, but has elected not to restate comparative information. As a result, the comparative information provided continues to be accounted for in accordance with the Group's previous accounting policy.

Until 31 December 2017 the Group classifies its financial assets as below categories:

- financial assets at fair value through profit or loss;
- loans and receivables;
- held-to-maturity investments; and
- available-for-sale financial assets.

The classification determined on the purpose for which the investments were acquired. Management determined the classification of its investments at initial recognition.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.10 Financial assets (Continued)

(e) Accounting policies applied until 31 December 2017 (Continued)

Subsequent measurement

The measurement at initial recognition did not change the adoption of HKFRS 9, see description above. Subsequent to the initial recognition, loans and receivables were subsequently carried at amortised cost using the effective interest method.

Impairment

The Group assessed at the end of each reporting period whether there was objective evidence that a financial asset or group of financial assets was impaired. A financial asset or a group of financial assets was impaired and loss allowance were incurred only if there was objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a "loss event") and that loss event (or events) had an impact on the estimated future cash flows of the financial asset or group of financial assets that could be reliably estimated.

Assets at amortised cost

For loans and receivables category, the amount of the loss was measured as the difference between the asset's carrying amount and the present value of estimated future cash flows (excluding future credit losses that had not been incurred) discounted at the financial asset's original effective interest rate. The carrying amount of the asset was reduced and the amount of the loss was recognised in profit or loss. If a loan or held-to-maturity investment had a variable interest rate, the discount rate for measuring any loss allowance was the current effective interest rate determined under the contract. As a practical expedient, the Group could measure loss allowance on the basis of an instrument's fair value using an observable market price.

If, in a subsequent period, the amount of the loss allowance decreased and the decrease could be related objectively to an event occurring after the loss allowance was recognised (such as an improvement in the debtor's credit rating), the reversal of the previously recognised loss allowance was recognised in profit or loss.

Impairment testing of trade receivables is described in note 3.1(b).

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.11 Offsetting financial instruments

Financial assets and liabilities are offset and the net amount reported in the balance sheet where the Group currently has a legally enforceable right to offset the recognised amounts, and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the company or the counterparty.

2.12 Government grants

Grants from the government are recognised at their fair value where there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions.

Government grants relating to costs are deferred and recognised in profit or loss over the period necessary to match them with the costs that they are intended to compensate.

Government grants relating to property, plant and equipment are included in liabilities as deferred government grants and are credited to profit or loss on a straight-line basis over the expected lives of the related assets.

2.13 Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined using the weighted average basis. The cost of finished goods and work in progress comprises materials, direct labour and an appropriate proportion of all production overhead expenditures. It excludes borrowing costs. Net realisable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses.

2.14 Trade and other receivables

Trade and other receivables are amounts due from customers for goods sold or services performed in the ordinary course of business. If collection of trade and other receivables is expected in one year or less, they are classified as current assets. If not, they are presented as non-current assets. They are generally due for settlement within 30-120 days and therefore are all classified as current.

Trade receivables are recognised initially at the amount of consideration that is unconditional unless they contain significant financing components, when they are recognised at fair value. The Group holds the trade receivables with the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method. See note 21 for further information about the Group's accounting for trade receivables and note 3.1 for a description of the Group's impairment policies.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.15 Cash and cash equivalents

For the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. Bank deposits with original maturities of more than three months are excluded from cash and cash equivalents.

2.16 Share capital

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

2.17 Trade and other payables

Trade payables are obligations to pay for goods and services provided to the Group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually paid within the normal operating cycle of the business. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognised initially at their fair value and subsequently measured at amortised cost using the effective interest method.

2.18 Borrowings

Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognised in the income statement over the period of the borrowings using the effective interest method.

Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the end of the reporting period.

2.19 Borrowing costs

General and specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalised during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale.

Other borrowing costs are expensed in the period in which they are incurred.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.20 Current and deferred income tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in the profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

(a) Current income tax

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where the Group operates and generates taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

(b) Deferred income tax

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognised if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled.

Deferred tax assets are recognised only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

Deferred tax liabilities and assets are not recognised for temporary differences between the carrying amount and tax bases of investments in foreign operations where the company is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

2 **SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES** (Continued)

2.21 Employees benefits

(a) Pension obligations

The Group contributes to various employee retirement benefit plans organised by municipal and provincial governments in Mainland China for its PRC based employees. Under these plans, the municipal and provincial governments undertake to assume the retirement benefit obligations of all existing and future retired PRC based employees of the Group. Contributions to these plans are expensed as incurred. The Group has no further payment obligations once the contributions have been paid.

The Group's contributions to the Mandatory Provident Fund Scheme established under the Hong Kong Mandatory Provident Fund Schemes Ordinance are expensed as incurred. Both the Group and its employees in Hong Kong are required to contribute 5% of each individual's relevant income with a maximum amount of HK\$1,500 per month as a mandatory contribution. Employees may also elect to contribute more than the minimum as a voluntary contribution. The assets of the scheme are held separately from those of the Group and managed by independent professional fund managers. The Group has no further payment obligations once the contributions have been paid.

(b) Profit-sharing and bonus plans

The Group recognises a liability and an expense for bonuses and profit-sharing, based on a formula that takes into consideration the profit attributable to the Company's shareholders after certain adjustments. The Group recognises a provision where contractually obliged or where there is a past practice that has created a constructive obligation.

2 **SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES** (Continued)

2.22 Provisions

Provisions for environmental restoration, restructuring costs and legal claims are recognised when: the Group has a present legal or constructive obligation as a result of past events; it is probable that an outflow of resources will be required to settle the obligation; and the amount has been reliably estimated. Restructuring provisions comprise lease termination penalties and employee termination payments. Provisions are not recognised for future operating losses.

Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as interest expense.

2.23 Revenue recognition

The Group manufactures and sells a range of organic acids products. Sales are recognised when control of the products has transferred, being when the products are delivered to the customers, and there is no unfulfilled obligation that could affect the customer's acceptance of the products. Delivery occurs when the products have been shipped to the specified location, the risks of obsolescence and loss have been transferred to the customer, and either the customer has accepted the products in accordance with the sales contract, the acceptance provisions have lapsed, or the group has objective evidence that all criteria for acceptance have been satisfied.

Revenue from the sale of goods is based on the price specified in the sales contracts. No element of financing is deemed present as the sales are made within the credit terms, which is consistent with market practice.

Receivable is recognised when the goods are delivered as this is the point in time that the consideration is unconditional because only the passage of time is required before the payment is due.

Deposit collected from the customers before product delivery is recognised as contract liabilities.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.24 Interest income

Interest income is recognised on a time-proportion basis using the effective interest method.

2.25 Research and development costs

Research costs are expensed as incurred. Costs incurred on development projects relating to the design and testing of new or improved products are recognised as an intangible asset when the technical feasibility and intention of completing the product under development has been demonstrated and the resources are available to do so, costs are identifiable and there is an ability to sell or use the asset that will generate probable future economic benefits. Such development costs are recognised as an asset and amortised on the straight-line basis to reflect the pattern in which the related economic benefits are recognised. Development costs that do not meet the above criteria are expensed as incurred. Development costs previously recognised as an expense are not recognised as an asset in a subsequent period.

2.26 Operating leases

Leases in which a significant portion of the risks and rewards of ownership retained by the lessor are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to the income statement on a straight-line basis over the period of the lease.

2.27 Dividend distribution

Dividend distribution to the Company's shareholders is recognised as a liability in the Group's and the Company's financial statements in the period in which the dividends are approved by the Company's shareholders or directors, where appropriate.

3 FINANCIAL RISK MANAGEMENT

3.1 Financial risk factors

The Group's activities expose it to a variety of financial risks, including foreign exchange risk, credit risk, liquidity risk and cash flow and fair value interest rate risk. The Group's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effect on the Group's financial performance.

(a) Foreign exchange risk

The Group mainly operates in the PRC. Substantially all of its assets, liabilities and capital expenditure were located or incurred in Mainland China. Sales are made to customers in the PRC as well as overseas customers while purchases are mainly from suppliers in the PRC. The Group is therefore exposed to foreign exchange risk arising from currency exposures, primarily with respect to United States Dollars ("USD").

Management periodically monitors foreign currency exposures and considers hedging significant foreign currency exposures should the need arises.

At 31 December 2018, if Rmb had weakened/strengthened by 5% against USD with all other variables held constant, post-tax profit for the year would have been approximately Rmb2,169,000 (2017: Rmb1,236,000) higher/lower, mainly as a result of foreign exchange gains/losses on translation of USD-denominated trade receivables, other payables, bank deposits and bank borrowings.

3 FINANCIAL RISK MANAGEMENT (Continued)

3.1 Financial risk factors (Continued)

(b) Credit risk

(i) Risk Management

The Group's credit risk arises from cash at banks and trade and bills receivables, other receivables and deposits. Management has a credit policy in place and the exposures to these credit risks are monitored on an ongoing basis. The carrying amounts of these balances represent the Group's maximum exposure to credit risk in relation to financial assets which are stated as follows:

	2018 Rmb′000	2017 Rmb′000
Trade, bills and other receivables and deposits excluding prepayments and		
valued added tax recoverable (Note 19)	103,520	94,618
Cash at banks (Note 23)	87,872	89,973
Maximum exposure to credit risk	191,392	184,591

As at 31 December 2018, substantially all of the Group's bank balances are deposited in major financial institutions located in the PRC. Management does not expect any losses from non-performance by these banks. The credit quality of cash and cash equivalents has been assessed by reference to external credit ratings or to historical information about the counterparty default rates. The existing counterparties do not have defaults in the past.

The credit period of the majority of the Group's trade receivables is due within 30 to 120 days and largely comprises amounts receivable from corporate customers.

In respect of trade receivables, the Group has policies in place to ensure that sales of products are made to customers with an appropriate credit history and the Group performs periodic credit evaluation of its customers, taking into account its financial position, past experience and other factors. The Directors consider the Group does not have a significant concentration of credit risk.

3 FINANCIAL RISK MANAGEMENT (Continued)

3.1 Financial risk factors (Continued)

- (b) Credit risk (Continued)
 - (ii) Impairment of financial assets

Trade receivables

The Group applies the HKFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables.

To measure the expected credit losses, trade receivables have been grouped with similar risk characteristics and collectively or individually assessing them for likelihood of recovery.

The Group categorises its trade receivables, except those individually assessed, based on geographical location and the days past due. The expected loss rates are based on the payment profiles of sales over a period of 12 months and the corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables.

Given the track record of regular repayment of trade receivables under the collective assessment, the directors are of the opinion that the risk of default by these customers is not significant, taking into account forwardlooking information on macroeconomic factors. Therefore, expected credit loss rate of these trade receivables is assessed to be insignificant.

For trade receivables relating to accounts which are long overdue with known insolvencies or non-response to collection activities, they are assessed individually for loss allowance. Accordingly, specific loss allowance of Rmb1,359,000 were made as at 31 Dec 2018.

3 FINANCIAL RISK MANAGEMENT (Continued)

3.1 Financial risk factors (Continued)

- (b) Credit risk (Continued)
 - (ii) Impairment of financial assets (Continued)

Previous accounting policy for impairment of trade receivables
In the prior year, the impairment of trade receivables was assessed based on the incurred loss model. Individual receivables which were known to be uncollectible were written off by reducing the carrying amount directly. The other receivables were assessed collectively to determine whether there was objective evidence that an impairment had been incurred but not yet been identified. For these receivables the estimated impairment losses were recognised in a separate provision for impairment. The Group considered that there was evidence of impairment if any of the following

- significant financial difficulties of the debtor
- probability that the debtor will enter bankruptcy or financial reorganisation, and
- default or late payments.

indicators were present:

Receivables for which an impairment provision was recognised were written off against the provision when there was no expectation of recovering additional cash.

Other financial assets at amortised cost

The directors of the Group consider the probability of default upon initial recognition of asset and whether there has been significant increase in credit risk on an ongoing basis. To assess whether there is a significant increase in credit risk the Group compares risk of a default occurring on the assets as at the reporting date with the risk of default as at the date of initial recognition. Especially the following indicators are incorporated.

- actual or expected significant adverse changes in business, financial economic conditions that are expected to cause a significant change to the company's ability to meet its obligations;
- actual or expected significant changes in the operating results of the company;
- significant changes in the expected performance and behavior of the company, including changes in the payment status of the third party.

3 FINANCIAL RISK MANAGEMENT (Continued)

- 3.1 Financial risk factors (Continued)
 - (b) Credit risk (Continued)
 - (ii) Impairment of financial assets (Continued)

 Other financial assets at amortised cost (Continued)

 Regardless of the analysis above, a significant increase in credit risk is presumed if a debtor is more than 30 days past due in making a contractual payment/repayable demanded.

A default on a financial asset is when the counterparty fails to make contractual payments/repayable demanded within 90 days of when they fail due.

Financial assets are written off when there is no reasonable expectation of recovery, such as a debtor failing to engage in a repayment plan with the Group. The Group categories a loan or receivable for write off when there is no reasonable expectations of recovering a financial asset in its entirety or a portion thereof. Where loans or receivables have been written off, the Group continues to engage in enforcement activity to attempt to recover the receivable due. Where recoveries are made, these are recognised in profit or loss.

The Group reviews regularly the recoverable amount of each individual receivable to ensure that adequate impairment losses are made for irrecoverable amounts. Over the term of the financial assets, the Group accounts for its credit risk by appropriately providing for expected credit losses on a timely basis. In calculating the expected credit loss rates, the Group considers historical loss rates for each category of debtors, and adjusts for forward looking macroeconomic data.

Impairment losses on other financial assets at amortised cost are presented as net impairment losses within the profit or loss. Subsequent recoveries of amounts previously written off are credited against the same line item.

3 FINANCIAL RISK MANAGEMENT (Continued)

3.1 Financial risk factors (Continued)

(c) Liquidity risk

The Group's primary cash requirements have been for construction of and upgrades on property, plant and equipment, repayment on related borrowings and payment for research and development expenses. The Group finances its working capital requirements through funds generated from operations and short-term bank borrowings.

Due to the dynamic nature of the underlying businesses, the Group's policy is to regularly monitor current and expected liquidity requirements, to ensure that it maintains sufficient reserves of cash and adequate lines of funding to meet its liquidity requirements in the short and long term.

As at 31 December 2018 and 2017, all of the Group's trade and bills payables, other payables and bank borrowings were all due for settlement contractually within 1 year.

The table below summarises the contractual undiscounted cash flows in relation to the Group's financial liabilities.

	2018	2017
	Rmb′000	Rmb′000
Trade and bills payables	19,781	73,505
Other payables	28,568	14,321
Bank borrowings and interest thereon	39,784	54,411

(d) Cash flow and fair value interest rate risk

The Group's income and operating cash flows are substantially independent of changes in market interest rates and the Group has no significant interest-bearing assets except for cash and bank balances, details of which are disclosed in Note 23. The Group's exposure to changes in interest rates is mainly attributable to its short-term bank borrowings. Management intends to draw short-term bank loans so as to increase flexibility in financing.

Borrowings issued at fixed rates expose the Group to fair value interest rate risk. Borrowings issued at variable rates expose the Group to cash flow interest-rate risk. The Group will review whether bank loans bearing fixed or floating rates should be drawn from time to time with reference to the trend of changes in interest rates. The Group has not used any interest rate swaps to hedge its exposure to interest-rate risk.

3 FINANCIAL RISK MANAGEMENT (Continued)

3.1 Financial risk factors (Continued)

(d) Cash flow and fair value interest rate risk (Continued)

At 31 December 2018, if the interest rates on borrowings had been 10 basis points higher/lower with all other variables held constant, post-tax profit for the year would have been approximately Rmb39,000 (2017: Rmb54,000) lower/ higher, mainly as a result of higher/lower interest expense on bank borrowings.

3.2 Capital risk management

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares, repurchase shares from shareholders or sell assets to reduce debt.

The Group monitors capital on the basis of the liabilities-to-assets ratio. This ratio is calculated as total liabilities divided by total assets. The Group aims to maintain the ratio at a reasonable level.

The liabilities-to-assets ratio at 31 December 2018 and 2017 was as follows:

	2018	2017
	Rmb′000	Rmb′000
Total liabilities	101,151	151,425
Total assets	732,018	732,382
The Later Control of the Control of	42.00/	20.70/
Liabilities-to-assets ratio	13.8%	20.7%

The decrease in liabilities-to-assets ratio is mainly due to the decrease in utilisation of bills payables and short-term bank borrowings to finance the Group's operations.

3.3 Fair value estimation

Majority of the carrying amount of the Group's financial assets, including cash and bank balances, pledged bank balances, trade and bills receivables, other receivables, and financial liabilities, including trade and bills payables, other payables and short-term bank borrowings, approximate their fair values due to their short maturities.

3.4 Offsetting financial assets and financial liabilities

No financial assets and financial liabilities were subject to offsetting, enforceable master netting arrangements and similar agreements as at 31 December 2018 and 2017.

4 CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

The preparation of financial statements requires the use of accounting estimates which, by definition, will seldom equal the actual results. Management also needs to exercise judgement in applying the Group's accounting policies.

Estimates and judgements are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that are believed to be reasonable under the circumstances.

(a) Impairment of property, plant and equipment and intangible assets

Property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. The recoverable amounts have been determined based on higher of fair value less cost of disposal or value-in-use calculations. These calculations require the use of judgements and estimates.

Management judgement is required in the area of asset impairment particularly in assessing: (i) whether an event has occurred that may indicate that the related asset values may not be recoverable; (ii) whether the carrying value of an asset can be supported by the recoverable amount, being the higher of fair value less costs of disposal and value-in-use which is the net present value of future cash flows which are estimated based upon the continued use of the asset in the business; and (iii) the appropriate key assumptions to be applied in preparing cash flow forecast including whether these cash flow forecast is discounted using an appropriate rate. Changing the assumptions selected by management in assessing impairment, including the discount rates, the gross profit margin or the revenue growth rate assumptions in the cash flow forecast, could affect the net present value used in the impairment test and as a result affect the Group's financial position and results of operations.

As at 31 December 2018, the Group has certain non-financial assets, including property, plant and equipment, land use rights and construction in progress related to the production plants in Lianyungang Changmao amounting to approximately RMB153 million. The production plants in Lianyungang commenced operations since early 2016 and have been operating at loss since its commencement of operations while planned production level is still yet to be attained.

4 CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS (Continued)

(a) Impairment of property, plant and equipment and intangible assets (Continued) In early 2018, Jiangsu Provincial authority has requested all the enterprises in Lianyungang Industrial Park ("Industrial Park") to suspend production due to certain enterprises in the Industrial Park continued to experience safety and environmental accidents. The production of Lianyungang Changmao was then suspended, as Lianyungang Changmao is located in Industrial Park. However, Lianyungang Changmao has strictly complied with various laws and regulations and carried out

Lianyungang Changmao is located in Industrial Park. However, Lianyungang Changmao has strictly complied with various laws and regulations and carried out plant construction and project approval work in accordance with national regulations since its incorporation. The Group has already registered with the relevant authority for restoration of production, which is pending for approval up to the date of this report. Management considered that the suspension shall be temporary.

As a result of the operating losses and temporary suspension of the production of Lianyungang Changmao, management has performed an impairment assessment on the non-financial assets of the plants as at 31 December 2018. Management has also performed sensitivity analysis over the key assumptions of the cash flow forecast, including future gross profit margin, revenue growth rate, discount rate and a further delay for restoration of production by 12 months, in order to assess the potential impact of a range of possible outcomes. Based on the results of the assessment, it is concluded that no provision for impairment of the above non-financial assets of Lianyungang Changmao is required.

(b) Net realisable value of inventories

The Group writes down inventories to net realisable value based on an assessment of the realisability of inventories. Provisions are made for inventories where events or changes in circumstances indicate that the balances may not be realised. The identification of obsolescence requires the use of judgement and estimates. Where the estimate is different from the original amount, such difference will impact the carrying value of inventories and net realisable value for the periods in which such estimate is changed. In addition, management has assessed the realisability of the inventories and considers that the provision for inventories impairment is adequate and reasonable in the current year.

4 CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS (Continued)

(c) Useful lives of property, plant and equipment

The Group's management determines the estimated useful lives, residual values and related depreciation charges for the Group's property, plant and equipment, with reference to the estimated periods that the Group intends to derive future economic benefits from use of these assets. This estimate is based on the historical experience of the actual useful lives of property, plant and equipment of similar nature and functions. Management will revise the depreciation charges where useful lives or residual values are different from previously estimated, or it will write-off or write-down technically obsolete or non-strategic assets that have been abandoned or sold.

(d) Trade and other receivables

The loss allowances for trade and other receivables are based on assumptions about risk of default and expected loss rates. The group uses judgement in making these assumptions and selecting the inputs to the impairment calculation, based on the group's past history, existing market conditions as well as forward looking estimates at the end of each reporting period. Details of the key assumptions and inputs used are disclosed in note 3.1(b).

(e) Income taxes and deferred tax

The Group is subject to income taxes in Mainland China. Judgement is required in determining the provision for income taxes. There are transactions and calculations during the ordinary course of business for which the ultimate tax determination is uncertain. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the period in which such determination is made.

Deferred income tax assets relating to certain temporary differences and tax losses are recognised when management considers it is likely that future taxable profits will be available against which the temporary differences or tax losses can be utilised. When the expectations are different from the original estimates, such differences will impact the recognition of deferred income tax assets and income tax charges in the period in which such estimates have been changed.

4 CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS (Continued)

(f) Research and development costs

Research costs are expensed as incurred. Costs incurred on development projects relating to the design and testing of new or improved products are recognised as an intangible asset when the technical feasibility and intention of completing the product under development has been demonstrated and the resources are available to do so, costs are identifiable and there is an ability to sell or use the asset that will generate probable future economic benefits. Significant judgement is required in determining the capitalisation of development costs. Development costs that are recognised as assets are amortised on the straight-line basis to reflect the pattern in which the related economic benefits are recognised. Development costs that do not meet the above criteria are expensed as incurred.

5 REVENUE AND SEGMENT INFORMATION

Executive directors are identified as the chief operating decision maker. Management has determined the operating segments based on the information reported to the executive directors for the purposes of allocating resources and assessing performance.

The Group is engaged in the production and sales of organic acids products. Resources of the Group are allocated based on what is beneficial to the Group in enhancing the value as a whole rather than any specific unit, and the executive directors consider the performance assessment of the Group should be based on the results of the Group as a whole. Therefore, management considers there to be only one operating segment under the requirement of HKFRS 8.

	2018 Rmb′000	2017 Rmb′000
Revenue from sales of goods, recognised at a point in time	639,120	630,841
An analysis of the Group's revenue by geographic location is as	follows:	
	2018	2017
	Rmb′000	Rmb′000
Mainland China	324,745	287,394
Europe	112,698	106,610
Asia Pacific	142,815	173,870
America	43,887	54,984
Others	14,975	7,983
	639,120	630,841

5 REVENUE AND SEGMENT INFORMATION (Continued)

Europe region mainly includes the Great British, Germany, Turkey, Spain and Italy whereas Asia Pacific region mainly includes Hong Kong, Indonesia, Australia, India, Thailand and Japan.

The analysis of revenue by geographic location is based on the country area in which the customer is located. No analysis of contribution by geographic location has been presented as the ratio of profit to revenue achieved for individual geographic location is not substantially out of line with the Group's overall ratio of profit to revenue.

As at 31 December 2018, all the Group's non-current assets (other than the deferred income tax assets) amounted to Rmb406,671,000 (2017: Rmb408,149,000) are located in Mainland China.

Included in the revenue from sales of goods, approximately Rmb33,580,000 (2017: Rmb51,729,000) was contributed by the Group's largest customer and the aggregate revenue from this customer represented approximately 5% (2017: 8%) of the total revenue of the Group. There are no single customers contributing over 10% of the Group's total revenue.

Assets and liabilities related to contract with customers

Contract liabilities of Rmb3,398,000 were recognised in relation to receipt in advance from customers for sales of goods not yet delivered and were previously included in other payables and accruals (Rmb2,279,000 as at 1 January 2018).

The Group has not recognised any contract assets related to contract with customers as at 1 January and 31 December 2018.

- (i) Significant changes in contract liabilities

 Contract liabilities have been increased by Rmb1,119,000 due to an increase in overall contract activities.
- (ii) Revenue recognised in relation to contract liabilities

 Revenue of Rmb2,279,000 is recognised in relation to contract liabilities in the year ended 31 December 2018 related to carried forward contract liabilities as at 1 January 2018. There is no revenue recognised in relation to contract liabilities satisfied on or before 1 January 2018.
- (iii) All contracts are for the periods of one year or less or are billed based on time incurred. As permitted under HKFRS 15, the transaction price allocated to these unsatisfied contracts is not disclosed.

6 OTHER INCOME AND OTHER GAINS/(LOSSES), NET

	1,737	(5,889)
Net exchange gains/(losses)	1,816	(3,033)
Loss on disposal of property, plant and equipment	(79)	(2,856)
Other gains/(losses), net		
	Rmb′000	Rmb′000
	2018	2017
	4,018	12,784
Others	2,357	2,423
Government grants (Note a)	1,618	9,574
Sales of scrap materials	43	787
Other income		
	Rmb′000	Rmb′000
	2018	2017
OTHER INCOME AND OTHER GAINS/ (LOSSES	• •	

Note:

⁽a) Government grants recognised during the year ended 31 December 2017 mainly included a grant totalling RMB7,221,000 in relation to an organic acid research project, which was recognised upon fulfilment of all relevant conditions during the year.

7 EXPENSES BY NATURE

	2018	2017
	Rmb′000	Rmb′000
Cost of inventories sold	310,764	335,175
Amortisation of patents (Note 14)	84	84
Amortisation of land use rights (Note 16)	699	731
Auditors' remuneration		
– Audit services	1,367	1,261
 Non-audit services 	_	114
Depreciation (Note 15)	33,587	37,091
Operating lease rentals in respect of land and buildings	611	592
Research and development costs	8,677	8,117
Written back for impairment of inventories	_	(1,622)
Loss allowance/(reversal of loss allowance) on financial asset	s 1,304	(178)
Staff costs (including emoluments of		
Directors and Supervisors) (Note 12)	69,859	69,044
Utilities	58,922	82,842
Other expenses	103,547	103,270
	589,421	636,521

Included in research and development costs are mainly expenditures incurred for the formulation, design, evaluation and application of various forms of organic acids products for commercial use. Management assessed that those internal projects are in the research and initial development stage, and did not recognise any of those expenditure as an asset.

8 FINANCE (COSTS)/INCOME, NET

	2018	2017	
	Rmb′000	Rmb′000	
Interest on bank borrowings	(1,149)	(1,291)	
Less: amounts capitalised on qualifying assets		1,059	
	(1,149)	(232)	
Interest income on bank deposits	296	261	
Finance (costs)/income, net	(853)	29	

9 INCOME TAX EXPENSE/(CREDIT)

PRC Corporate Income Tax ("CIT") is provided for on the basis of the profit for statutory financial reporting purposes, adjusted for income and expense items which are not assessable or deductible for income tax purposes. The Company, being qualified as a New and High Technology Enterprise, is entitled to a preferential CIT rate of 15%. Other subsidiaries of the Group in Mainland China are subject to a standard tax rate of 25%.

The amount of income tax charged to consolidated statement of comprehensive income represents:

2018	2017
Rmb′000	Rmb′000
9,852	_
(9)	25
(5,151)	(1,481)
4,692	(1,456)
	9,852 (9) (5,151)

9 INCOME TAX EXPENSE/(CREDIT) (Continued)

The tax on the Group's profit before income tax differs from the theoretical amount that would arise using the weighted average tax rate applicable to the results of the consolidated entities as follows:

	2018	2017
	Rmb′000	Rmb′000
Profit before income tax	54,601	1,244
Calculated at the tax rates applicable to results of the		
respective consolidated entities	5,257	(1,023)
Expenses not deductible for tax purposes	1,162	228
Tax losses for which no deferred income tax asset was		
recognised	533	958
Tax incentives for research and development expenses*	(2,198)	(1,540)
(Over)/under-provision in prior year	(9)	25
Others	(53)	(104)
Income tax expense/(credit)	4,692	(1,456)

^{*} According to relevant laws and regulations promulgated by the State Administration of Tax of the PRC effective from 2008 onwards, enterprises engaging in research and development activities are entitled to claim 175% (2017: 150%) of their qualified research and development expenses so incurred as tax deductible expenses when determining their assessable profits for the year ("Super Deduction"). The additional deduction of 75% (2017: 50%) of qualified research and development expenses is subject to the approval from the relevant tax authorities in the annual CIT filling. The Group has made its best estimate for the Super Deduction to be claimed in ascertaining the assessable profits for the years ended 31 December 2018 and 2017.

10 EARNINGS PER SHARE

The calculation of basic earnings per share for the year ended 31 December 2018 is based on the profit attributable to the equity holders of the Company of Rmb50,525,000 (2017: Rmb3,382,000) and 529,700,000 (2017: 529,700,000) weighted average number of shares in issue during the year.

The Company had no dilutive potential shares in issue during the year (2017: Nil).

11 DIVIDENDS

No interim dividend was declared during the year (2017: Nil). The dividends paid in 2018 and 2017 were Nil and Rmb10,594,000 (Rmb0.02 per share) respectively. A final dividend in respect of the year ended 31 December 2018 of Rmb0.05 per share, totalling Rmb26,485,000 is to be proposed at the Annual General Meeting on 10 May 2019. These financial statements do not reflect this dividend payable.

12 STAFF COSTS

Staff costs including Directors' and Supervisors' remuneration are as follows:

	2018	2017
	Rmb′000	Rmb′000
Salaries, wages and related welfare	56,302	55,062
Social security costs	6,713	6,953
Contribution to defined contribution retirement schemes (Note)	6,844	7,029
	69,859	69,044

Note: The Group is required to participate in defined contribution retirement schemes organised by the relevant local government authorities for its PRC based employees. Contributions to the retirement schemes are payable at a rate of 19% (2017: 19%) of the total salaries and allowances of the PRC based employees, subject to a ceiling, and the Group has no further retirement benefit obligations to all its existing and future retired PRC based employees.

13 EMOLUMENTS OF SUPERVISORS AND SENIOR MANAGEMENT

(a) The remuneration of each of the Supervisors of the Company for the year ended 31 December 2018 is set out as follows:

					Estimated money value	Retirement	
	Fees	Salaries	Discretionary Bonus	Housing Allowance	of other benefit	benefits contributions	Total
	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000
Ms. Zhou Rui Juan	15	48	-	-	-	-	63
Mr. Lu A Xing	6	180	-	-	-	19	205
Mr. Zhang Jun Peng	6	194	-	-	-	22	222
Prof. Jiang Yao Zhong	15	-	-	-	-	-	15
Mr. Geng Gang	15	-	-	-	-	-	15

The remuneration of each of the Supervisors of the Company for the year ended 31 December 2017 is set out as follows:

					Estimated		
					money value	Retirement	
			Discretionary	Housing	of other	benefits	
	Fees	Salaries	Bonus	Allowance	benefit	contributions	Total
	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000
Ms. Zhou Rui Juan	15	48	_	_	_	_	63
Mr. Lu A Xing	6	231	-	-	-	23	260
Mr. Zhang Jun Peng	6	212	_	-	-	21	239
Prof. Jiang Yao Zhong	15	-	-	-	-	-	15
Mr. Geng Gang	15	-	-	-	-	-	15

None of the supervisors received or will receive any retirement benefits or termination benefits during the financial year (2017: Nil).

13 EMOLUMENTS OF SUPERVISORS AND SENIOR MANAGEMENT (CONTINUED)

(b) Five highest paid individuals

Among the five highest paid individuals, two (2017: two) of them are Directors of the Company and the details of their remuneration are disclosed in Note 34(a). The emoluments of the remaining three highest paid individual are as follows:

	2018	2017
	Rmb′000	Rmb′000
Basic salaries, allowances and benefits in kind	1,456	1,456
Discretionary bonus	251	_
Retirement benefit contributions	102	96
	1,809	1,552

The emoluments of each of the above 3 employees were all less than HK\$1,000,000.

(c) Senior management remuneration by band All senior management's (who are not Directors nor Supervisors) emolument fall within the band of HK\$0 – HK\$1,000,000 (2017: same).

14 PATENTS

	2018	2017
	Rmb′000	Rmb′000
Net book amount, at 1 January	744	828
Amortisation charge (Note 7)	(84)	(84)
Net book amount, at 31 December	660	744
	2018	2017
	Rmb′000	Rmb′000
At cost	11,600	11,600
Accumulated amortisation	(10,940)	(10,856)
Net book amount, at 31 December	660	744

15 PROPERTY, PLANT AND EQUIPMENT

	Buildings Rmb′000	Plant and machinery Rmb'000	Equipment and motor vehicles Rmb'000	Total Rmb′000
At 1 January 2017				
Cost	178,741	401,895	41,277	621,913
Accumulated depreciation	(57,967)	(227,525)	(30,498)	(315,990)
Net book amount	120,774	174,370	10,779	305,923
Year ended 31 December 2017				
Opening net book amount	120,774	174,370	10,779	305,923
Additions	_	25	6	31
Transfer from construction in				
progress (Note 17)	_	31,959	1,639	33,598
Disposals	(318)	(2,780)	(126)	(3,224)
Depreciation (Note 7)	(8,275)	(26,636)	(2,180)	(37,091)
Closing net book amount	112,181	176,938	10,118	299,237
At 31 December 2017				
Cost	177,993	413,399	41,610	633,002
Accumulated depreciation	(65,812)	(236,461)	(31,492)	(333,765)
Net book amount	112,181	176,938	10,118	299,237
Year ended 31 December 2018				
Opening net book amount	112,181	176,938	10,118	299,237
Additions	_	_	8	8
Transfer from construction in				
progress (Note 17)	55	26,934	245	27,234
Disposals	(12)	(245)	(98)	(355)
Depreciation (Note 7)	(8,260)	(23,369)	(1,958)	(33,587)
Closing net book amount	103,964	180,258	8,315	292,537
At 31 December 2018				
Cost	178,032	439,112	40,248	657,392
Accumulated depreciation	(74,068)	(258,854)	(31,933)	(364,855)
Net book amount	103,964	180,258	8,315	292,537

Depreciation expense of Rmb27,750,000 (2017: Rmb30,114,000) and Rmb5,837,000 (2017: Rmb6,977,000) were charged in "cost of sales" and "administrative expenses" respectively for the year ended 31 December 2018.

16 LAND USE RIGHTS

The Group's interests in land use rights represent prepaid operating lease payments for land use rights on four pieces of land located in Mainland China and their net book value are analysed as follows:

	2018 Rmb′000	201 <i>7</i> Rmb′000
Net book amount, at 1 January Amortisation charge (Note 7)	26,642 (699)	27,373 (731)
Net book amount, at 31 December	25,943	26,642
	2018 Rmb′000	201 <i>7</i> Rmb′000
At cost Accumulated amortisation	34,259 (8,316)	34,259 (7,617)
Net book amount, at 31 December	25,943	26,642

17 CONSTRUCTION IN PROGRESS

	2018	2017
	Rmb′000	Rmb′000
At 1 January	79,826	59,574
Additions	34,939	53,850
Transfer to property, plant and equipment (Note 15)	(27,234)	(33,598)
At 31 December	87,531	79,826

During the year ended 31 December 2018, no borrowing costs were capitalised.

During the year ended 31 December 2017, the Group capitalised borrowing costs amounting to Rmb1,059,000 on qualifying assets. Borrowing costs were capitalised at the weighted average rate of its general borrowings of 2.7%.

18 SUBSIDIARIES

Details of the principal subsidiaries at 31 December 2018 are as follows:

Name	Place of establishment, operations and kind of legal entity	Particulars of registered and paid up capital	Interest directly held	Interest indirectly held	Principal activities
上海常茂生物化學工程 有限公司(Shanghai Changmao Biochemical Engineering Company Limited)	PRC, limited liability company	Rmb20,000,000	100%	-	Trading of organic acids products and property holding
上海醫學生命科學研究中心 有限公司(Shanghai Medical Life Science Research Centre Limited) (Note a)	PRC, limited liability company	Rmb15,384,600	57.44%	-	Research and development of medicine and nutraceutical products
常茂生物連雲港有限公司 (Changmao Biochemical Lianyungang Company Limited)	PRC, limited liability company	Rmb50,000,000	100%	-	Sales and production of food additives
Changmao (Hong Kong) Company Limited	Hong Kong, limited company	HKD1	100%	-	Trading of organic acids products
維萌(上海)商貿有限公司 (Shanghai Vitalements Trading Co., Ltd.)	PRC, limited liability company	Registered capital: Rmb1,000,000 Paid up capital: Rmb2,000	-	100%	General trading

Note a: No summarised financial information of Shanghai Medical Life Science Research Centre Limited is presented as the non-controlling interest is not material to the Group.

19 FINANCIAL INSTRUMENTS BY CATEGORY

	2018 Rmb′000	2017 Rmb′000
Financial assets at amortised cost as per balance sheet		
Trade and bills receivables	98,672	87,148
Other receivables and deposits excluding prepayments		
and value-added tax receivables	4,848	7,470
Pledged bank balances	2,774	15,671
Cash and bank balances	85,098	74,302
Total	191,392	184,591
	2012	201=
	2018 Rmb′000	201 <i>7</i> Rmb′000
	KIIID UUU	KIIID UUU
Financial liabilities at amortised cost as per balance sheet		
Bank borrowings	39,311	54,007
Trade and bills payables	19,781	73,505
Other payables excluding accruals and contract liabilities	28,568	14,321
Total	87,660	141,833
INVENTORIES		
	2018	2017
	Rmb′000	Rmb′000
Raw materials	43,192	47,864
Work-in-progress	6,642	16,878
Finished goods – at cost	58,190	50,593
	108,024	115,335

As at 31 December 2018, provision for impairment of inventories amounting to Rmb1,321,000 (2017: Rmb1,321,000).

The cost of inventories recognised as expense and included in "cost of sales" amounted to Rmb310,764,000 (2017: Rmb335,175,000) which included provision for inventories to net realisable value of Rmb Nil (2017: reversal of provision for inventories to net realisable value of Rmb1,622,000).

20

21 TRADE AND BILLS RECEIVABLES

	2018 Rmb′000	201 <i>7</i> Rmb′000
Trade receivables Bills receivables	98,672 —	86,248 900
	98,672	87,148

(a) The credit terms of trade receivables range from 30 to 120 days and the ageing analysis which is based on the invoice date of trade receivables is as follows:

	2018 Rmb′000	201 <i>7</i> Rmb′000
	KIIID 000	
0 to 3 months	94,340	83,330
4 to 6 months	4,972	2,919
Over 6 months	719	1,984
	100,031	88,233
Less: Loss allowance (Note 3.1)	(1,359)	(1,985)
	98,672	86,248

- (b) The maturity dates of bills receivables ranged from 60 to 180 days.
- (c) Loss allowance of trade receivables

The Group applies the HKFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. This has not resulted in a change to the loss allowance of trade receivables as at 1 January 2018. Note 3.1(b) provides for details about the allowance.

Information about the impairment of trade receivables and the Group's exposure to foreign exchange risk and credit risk can be found in note 3.1.

21 TRADE AND BILLS RECEIVABLES (Continued)

(c) Loss allowance of trade receivables (continued)

The closing loss allowances for all trade receivables reconcile to the opening loss allowances are as follows:

	Rmb′000
Loss allowance as at 1 January 2017 under HKAS 39	1,711
Trade receivables written off during the year as uncollectible	(31)
Loss allowance for trade receivables	305
Loss allowance as at 31 December 2017 under HKAS 39 and 1 January 2018 under HKFRS 9	1,985
Trade receivables written off during the year as uncollectible	(1,686)
Loss allowance for trade receivables	1,060
Loss allowance as at 31 December 2018 under HKFRS 9	1,359

Any loss allowance of trade receivables is separately presented in the consolidated statement of comprehensive income. The amounts charged to the allowance account are generally written off, when there is no expectation of recovering additional cash.

(d) The carrying amounts of trade and bills receivables approximate their fair values and are denominated in the following currencies:

	2018	2017
	Rmb′000	Rmb′000
Rmb	25,536	30,357
USD	73,136	56,791
	98,672	87,148

(e) The maximum exposure to credit risk at the reporting date is the fair value of each class of receivables mentioned above. The Group does not hold any collateral as security.

22 OTHER RECEIVABLES, DEPOSITS AND PREPAYMENTS

	2018	2017
	Rmb′000	Rmb′000
Prepayments and deposits	8,307	9,148
Value-added tax receivables	<i>7,</i> 595	11,760
Other receivables	928	2,558
	16,830	23,466

23 PLEDGED BANK BALANCES AND CASH AND BANK BALANCES

	2018	2017
	Rmb′000	Rmb′000
Long-term bank deposits	_	1,700
Short-term bank deposits with original		
maturities of over 3 months	3,700	3,850
Cash and cash equivalents	81,398	68,752
Cash and bank balances	85,098	74,302
Pledged bank balances	2,774	15,671
Total	87,872	89,973
	2018	2017
	Rmb′000	Rmb′000
Denominated in:		
– Rmb	70,089	67,735
– USD	17,381	22,198
- HKD	402	40
	87,872	89,973

The effective interest rate on long-term bank deposits and short-term bank deposits with original maturities of over 3 months are ranged from 1.35% to 2.25% (2017: same) per annum. These deposits have remaining maturities ranged from 3 months to 5 months (2017: 1 month to 1.5 years) as at 31 December 2018.

23 PLEDGED BANK BALANCES AND CASH AND BANK BALANCES (Continued)

Cash at banks earn interest at floating rates based on daily bank deposit rates.

The conversion of Renminbi denominated balances into foreign currencies and the remittance of these funds out of the Mainland China is subject to relevant rules and regulations of foreign exchange control promulgated by the PRC government.

Bank balances of Rmb2,774,000 (2017: Rmb15,671,000) have been pledged to a bank to secure the Group's bills financing facilities as at 31 December 2018.

24 SHARE CAPITAL

Registered, issued and fully paid:

Share ca	.pital
Number of	
shares at	Nomina
Rmb0.10	value

each Rmb'000

52,970

At 31 December 2018 and 2017

As at 31 December 2018 and 2017, the share capital of the Company comprised 2.5 million domestic shares, 343.5 million promoter foreign shares and 183.7 million H shares. The H shares rank pari passu with the domestic shares and promoter foreign shares in all aspects and rank equally for all dividends or distributions declared, paid or made except that all

529,700,000

shares may only be subscribed by legal or natural persons of Hong Kong, Macau, Taiwan or any country other than the PRC.

dividends in respect of H shares are to be paid by the Company in Hong Kong dollars and H

25 RESERVES

		Statutory				
	Share	common	Capital	Exchange	Retained	
	premium	reserve	reserve	reserve	earnings	Total
	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000
At 1 January 2017	102,559	78,791	461	2	351,778	533,591
Transfer to statutory common reserve	_	1,170	_	_	(1,170)	_
Profit for the year	_	_	_	_	3,382	3,382
Other comprehensive income					3,302	3,302
- currency translation						
difference – Group	_	_	_	(2)	_	(2)
Final dividend for the year ended				(/		(/
31 December 2016	_	_	_	_	(10,594)	(10,594)
At 31 December 2017	102,559	79,961	461	_	343,396	526,377
		Statutory				
	Share	,	Canital	Evehango	Retained	
	premium	common	Capital	Exchange reserve		Total
	Rmb′000	reserve Rmb′000	reserve Rmb'000	Rmb′000	earnings Rmb′000	Rmb'000
	KIIID UUU	KIIID UUU	KIIID UUU	KIIID UUU	KIIID UUU	KIIID UUU
At 1 January 2018	102,559	79,961	461	_	343,396	526,377
Transfer to statutory common reserve	_	7,272	_	_	(7,272)	_
Profit for the year	_		_	_	50,525	50,525
Other comprehensive income					/	/
- currency translation						
difference – Group	_	_	_	1	_	1
At 31 December 2018	102,559	87,233	461	1	386,649	576,903

25 RESERVES (Continued)

Statutory common reserve

According to the Company's Articles of Association, the Company is required to transfer 10% of its profit after tax, as determined in accordance with the PRC accounting rules and regulations, to statutory common reserve until the reserve balance reaches 50% of the registered capital. The transfer to this reserve must be made before distribution of a dividend to shareholders.

Statutory common reserve can be used to make good previous years' losses, if any, to expand the business operations of the Company and may be converted into share capital by the issuance of new shares to shareholders in proportion to their existing shareholdings or by increasing the par value of the shares currently held by them, provided that the balance after such issue is not less than 25% of the registered capital of the Company.

26 TRADE AND BILLS PAYABLES

	2018 Rmb′000	201 <i>7</i> Rmb′000
Trade payables Bills payables	10,535 9,246	21,267 52,238
bilis payables	19,781	73,505

(a) The ageing analysis of trade payables which is based on the invoice date of trade payables is as follows:

	2018 Rmb′000	201 <i>7</i> Rmb′000
0 to 6 months	10,247	21,062
7 to 12 months	40	7
Over 12 months	248	198
	10,535	21,267

- (b) The maturity dates of bills payables are normally within 6 months.
- (c) The carrying amounts of trade and bills payables approximate their fair values and are all denominated in Rmb.

27 CONTRACT LIABILITIES, OTHER PAYABLES AND ACCRUALS

	2018	2017
	Rmb′000	Rmb′000
D (1)	2.425	2.066
Deferred government subsidy	2,435	2,966
Construction payables	10,767	8,722
Provision for utilities	4,234	3,852
Contract liabilities (2017: Receipt in advance)	3,398	2,279
Others	18,166	5,599
	39,000	23,418
Less: Non-current portion		
Deferred government subsidy	(1,945)	(2,430)
Current portion	37,055	20,988

28 BANK BORROWINGS

The maturity of borrowings is as follows:

	2018 Rmb'000	201 <i>7</i> Rmb′000
Within 1 year	39,311	54,007
Denominated in:		
– RMB	1,000	5,000
- USD	38,311	49,007
	39,311	54,007

The carrying amounts of the Group's bank borrowings approximate their fair values.

As at 31 December 2018, the effective interest rate of the bank borrowings was 3.8% (2017: 2.7%).

29 DEFERRED INCOME TAX

The gross movement on the deferred income tax account is as follows:

	2018	2017
	Rmb′000	Rmb′000
At 1 January	8,304	6,823
Credited to the statement of comprehensive income (Note 9)	5,151	1,481
At 31 December	13,455	8,304

The movements in deferred income tax assets and liabilities during the year, without taking into consideration of the offsetting of balances within the same tax jurisdiction, are as follows:

Deferred income tax assets:

	Deferred		Tax	
	income	Provisions	losses	Total
	Rmb′000	Rmb′000	Rmb′000	Rmb′000
At 1 January 2017 (Charged)/credited to the consolidated	1,556	1,330	4,277	7,163
statement of comprehensive income	(1,107)	(267)	2,999	1,625
At 31 December 2017 (Charged)/credited to the consolidated	449	1,063	7,276	8,788
statement of comprehensive income	(51)	(62)	5,274	5,161
At 31 December 2018	398	1,001	12,550	13,949

29 DEFERRED INCOME TAX (Continued)

Deferred income tax liabilities:

	Deferred expense Rmb'000	Accelerated tax depreciation Rmb'000	Fair value gain on patents Rmb'000	Total Rmb′000
At 1 January 2017 Charged/(credited) to the consolidated	_	133	207	340
statement of comprehensive income	67	98	(21)	144
At 31 December 2017 Charged/(credited) to the consolidated	67	231	186	484
statement of comprehensive income	(67)	98	(21)	10
At 31 December 2018	-	329	165	494

Deferred income tax assets are recognised for tax losses carry-forwards to the extent that the realisation of the related tax benefits through the future taxable profits is probable. The Group did not recognise deferred income tax assets of approximately Rmb2,319,000 (2017: Rmb1,810,000) in respect of losses amounting to approximately Rmb9,277,000 (2017: Rmb7,238,000) that can be carried forward against future taxable income. The unrecognised tax losses will expire in the following years:

	2018	2017
	Rmb′000	Rmb′000
2020	1,452	1,452
2021	1,901	1,901
2022	3,789	3,885
2023	2,135	_
	9,277	7,238

The Group had no unrecognised deferred income tax liabilities as at 31 December 2018 (2017: Nil).

30 NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT

(a) Reconciliation of profit before income tax to net cash generated from operations

	2018	2017
	Rmb′000	Rmb′000
Profit before income tax	54,601	1,244
Adjustments for:		
Interest income	(296)	(261)
Interest expense	1,149	232
Unrealised exchange difference	(146)	(1,609)
Government grants	(1,618)	(9,574)
Amortisation of patents	84	84
Depreciation	33,587	37,091
Loss on disposal of property, plant and equipment	79	2,856
Amortisation of land use rights	699	731
Written back for impairment of inventories	_	(1,622)
Loss allowance/(reversal of loss allowance) on		
financial assets	1,304	(178)
	89,443	28,994
Changes in working capital:		
Inventories	7,311	(12,002)
Trade and bills receivables, other receivables,		
deposits and prepayments	(5,407)	6,754
Trade and bills payables, contract liabilities,		
other payables and accruals	(39,528)	44,158
Cash generated from operations	51,819	67,904

(b) Analysis of changes in financing during the year

	Bank borro	wings	Dividends p	ayable
	2018	2017	2018	2017
	Rmb′000	Rmb′000	Rmb′000	Rmb′000
At 1 January	54,007	30,000	_	_
New bank borrowings	73,004	105,945	_	_
Repayment of bank borrowings	(88,342)	(79,843)	-	_
Exchange difference	642	(2,095)	_	_
2016 final dividend	_	_	_	10,594
Dividends paid	_	_	_	(10,594)
At 31 December	39,311	54,007	_	_

31 COMMITMENTS

(a) Capital commitments for property, plant and equipment are as follows:

	2018	2017
	Rmb′000	Rmb′000
Contracted but not provided for	12,328	7,261

(b) Commitments under operating leases

The Group leases various offices and warehouses under non-cancellable operating leases. At 31 December 2018, the Group and the Company had future aggregate minimum lease payments in respect of land and buildings under non-cancellable operating leases as follows:

	2018	2017
	Rmb′000	Rmb′000
Not later than one year	260	518
Later than one year and not later than five years	_	248
	260	766

32 RELATED PARTY TRANSACTIONS

Key management compensation

	2018	2017
	Rmb′000	Rmb′000
	2.242	
Salaries and other short-term employee benefits	2,249	1,467
Retirement benefit contributions	43	63
	2,292	1,530

33 BALANCE SHEET AND RESERVE MOVEMENT OF THE COMPANY BALANCE SHEET OF THE COMPANY

AS AT 31 December 2018

		2018	2017
		Rmb′000	Rmb′000
ACCETC			
ASSETS			
Non-current assets		210.604	200 575
Property, plant and equipment		210,604	209,575
Land use rights		7,932	8,172
Construction in progress		8,059	12,773
Investments in subsidiaries		72,794	72,794
Deferred income tax assets		932	1,712
		300,321	305,026
Current assets			
Inventories		89,593	94,463
Trade and bills receivables		98,145	84,977
Other receivables, deposits and prepayments		7,630	12,586
Amounts due from subsidiaries		10,134	3,448
Loans to a subsidiary		185,000	180,000
Income tax recoverable		_	1,223
Pledged bank balances		2,774	15,671
Cash and bank balances		79,103	56,038
		472,379	448,406
Total assets		772,700	753,432
EQUITY			
Capital and reserves attributable to the			
Company's equity holders			
Share capital		52,970	52,970
Reserves	Note (a)	625,167	551,774
Total equity		678,137	604,744

33 BALANCE SHEET AND RESERVE MOVEMENT OF THE COMPANY (Continued)

BALANCE SHEET OF THE COMPANY (Continued)

AS AT 31 December 2018

		2018	2017
		Rmb′000	Rmb′000
LIABILITIES			
Non-current liability			
Other payable		1,945	2,430
Current liabilities			
Trade and bills payables		19,746	72,228
Contract liabilities, other payables and accruals		30,996	16,171
Amount due to a subsidiary		_	3,852
Income tax payable		2,565	_
Bank borrowings		39,311	54,007
		92,618	146,258
Total liabilities		94,563	148,688
Total equity and liabilities	,	772,700	753,432

The balance sheet of the Company was approved by the Board of Directors on 12 March 2019 and was signed on its behalf

Rui Xin Sheng
Director

Pan Chun Director

33 BALANCE SHEET AND RESERVE MOVEMENT OF THE COMPANY (Continued)

Note (a) Reserve movement of the Company

	Company						
		Statutory					
	Share	common	Retained				
	premium	reserve	earnings	Total			
	Rmb′000	Rmb′000	Rmb′000	Rmb′000			
At 1 January 2017	102,559	78,791	368,427	549,777			
Transfer to statutory common							
reserve	_	1,170	(1,170)	_			
Profit and total comprehensive							
income for the year	_	_	12,591	12,591			
Final dividend for the year							
ended 31 December 2016	_	_	(10,594)	(10,594)			
At 31 December 2017	102,559	79,961	369,254	551,774			
		Statutory					
	Share	common	Retained				
	premium	reserve	earnings	Total			
	Rmb′000	Rmb′000	Rmb′000	Rmb′000			
At 1 January 2018	102,559	79,961	369,254	551,774			
Transfer to statutory common	.02,000	, 3,30.	303,23.	33.,,,,			
reserve	_	7,272	(7,272)	_			
Profit and total comprehensive		,,_,_	(,,=,=)				
income for the year	_	_	73,393	73,393			
			,				
At 31 December 2018	102,559	87,233	435,375	625,167			

34 BENEFITS AND INTERESTS OF DIRECTORS

(a) Directors' and chief executive's emoluments

The remuneration of each of the Directors and chief executive officer's of the Company for the year ended 31 December 2018 is set out as follows:

Name of Director					Estimated		
	Fees Salaries Rmb'000 Rmb'000		Housing allowance Rmb'000	walue of other benefits Rmb'000	Retirement benefit contributions	Total	
	KMD UUU	Rmb′000	KMD 000	KMD UUU	KMD 000	Rmb′000	Rmb′000
Executive director							
Mr. Rui Xin Sheng	320	480	603	-	-	-	1,403
Mr. Pan Chun (Note (i))	100	545	201	-	-	43	889
Non-executive director							
Mr. Zeng Xian Biao	50	-	101	-	-	-	151
Mr. Yu Xiao Ping	50	-	101	-	-	-	151
Ms. Leng Yi Xin	50	-	101	-	-	-	151
Mr. Wang Jian Ping	50	-	101	-	-	-	151
Independent non-executive director							
Prof. Ouyang Ping Kai	60	-	-	-	-	-	60
Prof. Yang Sheng Li	60	-	-	-	-	-	60
Ms. Wei Xin	60	-	-	-	-	-	60
Ms. Au Fung Lan	60	_	_	-	-	_	60

34 BENEFITS AND INTERESTS OF DIRECTORS (Continued)

(a) Directors' and chief executive's emoluments (Continued)

The remuneration of each of the Directors and chief executive officer's of the Company for the year ended 31 December 2017 is set out as follows:

					Estimated		
					money		
					value of	Retirement	
			Discretionary	Housing	other	benefit	
Name of Director	Fees	Salaries	bonus	allowance	benefits	contributions	Total
	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000
Executive director							
Mr. Rui Xin Sheng	320	504	-	-	-	23	847
Mr. Pan Chun (Note (i))	100	543	-	-	-	40	683
Non-executive director							
Mr. Zeng Xian Biao	50	-	-	-	-	-	50
Mr. Yu Xiao Ping	50	-	-	-	-	-	50
Ms. Leng Yi Xin	50	-	-	-	-	-	50
Mr. Wang Jian Ping	50	-	-	-	-	-	50
Independent non-executive							
director							
Prof. Ouyang Ping Kai	60	-	-	-	-	-	60
Prof. Yang Sheng Li	60	-	-	-	-	-	60
Ms. Wei Xin	60	-	-	-	-	-	60
Ms. Au Fung Lan	60	-	-	-	-	-	60
Prof. Yang Sheng Li Ms. Wei Xin	60	- - -	- - -	- - -	- - -	- - -	60

Notes:

- (i) Mr. Pan is also the chief executive officer of the Company
- (ii) None of the Directors waived any emoluments during the years ended 31 December 2018 and 2017.
- (iii) No remuneration paid to or receivables by the Directors of the Company in respect of accepting office as director or director's other services in connection with the management of the affairs of the Company or its subsidiary undertaking.

34 BENEFITS AND INTERESTS OF DIRECTORS (Continued)

(b) Directors' retirement benefits and termination benefits

None of the directors received or will receive any retirement benefits or termination benefits during the financial year (2017: Nil).

- (c) Consideration provided to third parties for making available directors' services
 - During the financial year ended 31 December 2018, the Company did not pay consideration to any third parties for making available directors' services (2017: Nil).
- (d) Information about loans, quasi-loans and other dealings in favour of directors, controlled bodies corporate by and connected entities with such directors
 - As at 31 December 2018, there were no loans, quasi-loans and other dealing arrangements in favour of directors, controlled bodies corporate by and controlled entities with such directors (2017: Nil).
- (e) Directors' material interests in transactions, arrangements or contracts

No significant transactions, arrangements and contracts in relation to the Group's business to which the Company was a party and in which a director of the Company had a material interest, whether directly or indirectly, subsisted at the end of the year or at any time during the year. (2017: Nil)

FIVE YEAR SUMMARY

Consolidated results Revenue 561,669 514,7	79 594,402 20 34,437 87 364	630,841	639,120
	20 34,437	,	639,120
Revenue 561,669 514,/	20 34,437	,	639,120
	•	1,215	
0	•	1,215	FF 4F4
	364	20	55,454
Finance (costs)/income, net (3,152) 6		29	(853)
Profit before income tax 41,915 51,0	007 34,801	1,244	54,601
Income tax (expense)/credit (4,497) (5,8			(4,692)
meome tax (expense)/credit (4,437) (3,0	(1,403)	1,430	(4,032)
Profit for the year 37,418 45,1	46 33,316	2,700	49,909
Profit for the year attributable to:			
Equity holders of the Company 37,223 45,2	74 33,172	3,382	50,525
• •	28) 144		(616)
Troth definitioning interest	20,	(002)	(0.0)
Dividends 11,653 13,7	72 10,594	_	26,485
Consolidated assets and liabilities			
Total non-current assets 405,497 402,7	48 400,861	416,937	420,620
			,
Total current assets 286,798 327,4	56 275,497	315,445	311,398
Total current liabilities (156,138) (160,6	(33) (85,044)	(148,511)	(98,712)
Net current assets 130,660 166,8	190,453	166,934	212,686
Total assets less current liabilities 536,157 569,5			633,306
Total non-current liabilities (343) (2	64) (2,461)	(2,914)	(2,439)
Net assets 535,814 569,3	07 588,853	580,957	630,867
	1		
Earnings per share			
- basic and diluted Rmb0.070 Rmb0.0	85 Rmb0.063	Rmb0.006	Rmb0.095

GLOSSARY

Board of Directors of the Company

CG Code Code provisions of Corporate Governance Code in

appendix 14 of the Listing Rules

Changmao or the Company Changmao Biochemical Engineering Company Limited

Changzhou Xinsheng 常州新生生化科技開發有限公司

Chirotechnology Centre the Jiangsu Biochemical Chirotechnology Research

Centre

CIT Corporate Income Tax

Concurrent Production Technology The concurrent production technology for the

production of fumaric acid and malic acid

Director(s) Director(s) of the Company

Domestic Shares domestic shares of the Company

Foreign Shares foreign shares of the Company

GEM Growth Enterprise Market of the Exchange

GMP Good Manufacturing Practices

Group The Company and its subsidiaries

H Shares H shares of the Company

HK Biochem Ltd Hong Kong Bio-chemical Advanced Technology

Investment Company Limited

HK Xinsheng Ltd Hong Kong Xinsheng Pioneer Investment Company

Limited

Lianyungang Changmao Changmao Biochemical Lianyungang Company

Limited, a subsidiary of the Company

Listing Rules Rules Governing the Listing of Securities on The Stock

Exchange

GLOSSARY

Main Board the securities market operated by the Stock Exchange

prior to the establishment of GEM (excluding the options market) which continues to be operated by the Stock Exchange in parallel with GEM, and for avoidance of doubt, it does not include GEM for the

purpose hereof

Model Code Model Code for Securities Transactions by Directors of

Listed Issuers as set out in Appendix 10 to the Listing

Rules

PQQ Pyrroloquinoline quinone

PRC The People's Republic of China

Rmb Renminbi

SFO Securities and Futures Ordinance

Shanghai Changmao Biochemical Engineering

Company Limited, a subsidiary of the Company

Shanghai Life Science Research Centre Limited

Shuguang Factory Changzhou Shuguang Factory (常州曙光化工廠)

Stock Exchange The Stock Exchange of Hong Kong Limited

Supervisor(s) Supervisor(s) of the Company

USD United States Dollars